WO2021018114A1 - 抗人p40蛋白域抗体及其用途 - Google Patents

抗人p40蛋白域抗体及其用途 Download PDF

Info

Publication number
WO2021018114A1
WO2021018114A1 PCT/CN2020/105039 CN2020105039W WO2021018114A1 WO 2021018114 A1 WO2021018114 A1 WO 2021018114A1 CN 2020105039 W CN2020105039 W CN 2020105039W WO 2021018114 A1 WO2021018114 A1 WO 2021018114A1
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
seq
antibody
amino acid
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2020/105039
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
夏瑜
王忠民
张鹏
李百勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akeso Pharmaceuticals Inc
Original Assignee
Akeso Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2022001305A priority Critical patent/MX2022001305A/es
Priority to EP20847243.1A priority patent/EP4008727A4/en
Priority to CA3145909A priority patent/CA3145909A1/en
Priority to PH1/2022/550223A priority patent/PH12022550223A1/en
Priority to AU2020320910A priority patent/AU2020320910A1/en
Priority to KR1020227006902A priority patent/KR20220038775A/ko
Priority to US17/631,797 priority patent/US12595300B2/en
Priority to BR112022001632A priority patent/BR112022001632A2/pt
Application filed by Akeso Biopharma Inc filed Critical Akeso Biopharma Inc
Priority to JP2022505553A priority patent/JP7638955B2/ja
Publication of WO2021018114A1 publication Critical patent/WO2021018114A1/zh
Priority to IL290167A priority patent/IL290167A/en
Anticipated expiration legal-status Critical
Priority to ZA2022/02380A priority patent/ZA202202380B/en
Priority to JP2025024929A priority patent/JP2025081517A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5434—IL-12
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin

Definitions

  • the invention belongs to the field of medicine, and specifically relates to a monoclonal antibody that blocks the function of the interleukin IL-12/IL-23 p40 protein domain and its application.
  • Interleukin 12 also known as cytotoxic lymphocyte maturation factor (CLMF), or NK cell stimulation factor (natural killer cell stimulation factor, NKSF), is one of the interleukin family member.
  • IL-12 has a unique heterodimer structure. It is a glycosylated peptide chain (relative molecular mass of 75,000 Daltons) covalently linked by two protein domains of p40 and p35 through disulfide bonds.
  • the chain (p40) is composed of 306 amino acids, including 10 cysteine residues and 4 potential glycosylation sites
  • the light chain (p35) is composed of 197 amino acids, including 7 cysteine residues And 3 potential glycosylation sites.
  • Interleukin 23 is a new member of the interleukin-12 (IL-12) cytokine family discovered by Oppmann in 2000. Interleukin 23 is composed of the p19 protein domain and the p40 protein domain of IL-12. A compound cytokine with biological activity formed by covalently connecting disulfide bonds. IL-23 can be secreted by activated antigen presenting cells and dendritic cells. IL-23 binds to its receptor IL-23R and IL-12R ⁇ 1, but does not bind to IL-12R ⁇ 2 (Oppmann B et al. Immunity, 2000, 13(5): 715-725).
  • IL-23 and IL-12 have the same signal transduction pathway such as Janus kinase Tyk2, Jak2 and STATs, but each affects different T cells.
  • IL-23 can induce the rapid proliferation of memory T cells CD4 + , while IL-12 stimulates the proliferation of virgin CD4 + T cells. Similar to IL-12, human IL-23 stimulates IFN- ⁇ production and proliferation in PHA-activated T cells and CD45RO + T cells. Antagonizing the common subunit p40 of IL-12 and IL-23 can effectively antagonize the IL-12 and IL-23 pathways simultaneously.
  • Interleukin-12 is mainly produced by dendritic cells, macrophages, B lymphocytes and other antigen-presenting cells (APC), which can enhance the cytotoxic effects of NK cells (natural killer cells) and Tc cells (cytotoxic T cells); Stimulate resting or activated T cells and NK cells to produce interferon ⁇ (IFN- ⁇ ); promote the differentiation of Th0 to Th1.
  • IFN- ⁇ interferon ⁇
  • IL-12 plays an extremely important role in the body’s early non-specific immunity and subsequent antigen-specific adaptive immune processes.
  • IL-12 It is a multifunctional immune modulator (Manetti R et al. Journal of Experimental Medicine, 1993, 177(4): 1199-1204).
  • the role of IL-12 in the process of autoimmunity induction is as follows: (1) Promote the differentiation and proliferation of antigen-specific Th1 cells and produce a variety of cytokines, enhancing Th1-type immune response; (2) Stimulating mononuclear macrophages to produce more This kind of active medium enhances the cytotoxicity of immunocompetent cells and causes self-tissue damage; IL-12 also participates in antibody-mediated autoimmunity.
  • IL-23 plays an important role in a variety of immune diseases and is believed to be involved in the pathogenesis of psoriasis.
  • the abnormal accumulation of IL-2 and TNF-a in the skin lesions of psoriasis promotes the occurrence and development of psoriasis, and it is believed that the lymphocytes in the skin lesions secrete numerous cytokines, forming the main Th1 cytokine
  • the huge cell network is an important pathological basis for disease.
  • the Th1 cytokine secreted by DC seems to be the initiating factor of psoriasis.
  • Mature DC can increase the expression of IFN- ⁇ and IL-12.
  • the specific mechanism of mental, genetic and infectious factors in the pathogenesis is unknown.
  • IL-12 mediates T cells to the skin surface to induce the onset of psoriasis through skin lymphocyte antigens. Rosmarin et al. analyzed the structure, receptor and function of IL-12 and believed that psoriasis could be treated by changing the level of IL-12 ( Rosmarin D et al. Journal of drugs in dermatology, 2005, 4(3): 318-325).
  • Systemic lupus erythematosus is a complex systemic autoimmune disease.
  • Conventional treatments are mostly hormones and immunosuppressive agents.
  • STELARA a product of the well-known pharmaceutical company Johnson & Johnson (ustekinumab) is a completely human IL-12 and IL-23 antagonist, which has been approved by the US FDA for the treatment of SLE, proving that anti-IL-12 p40 antibody is effective in the treatment of systemic lupus erythematosus (SLE) Sex (Janssen R&D's STELARA (ustekinumab) Shows Positive Results In Treatment of Systemic Lupus Erythematosus in Phase II Trial).
  • IL-12 and IL-23 play an extremely important role in the induction of autoimmunity and the maintenance of immune response. Therefore, blocking the production or signal transduction of IL-12 and IL-23 can prevent or Prevent the occurrence and development of autoimmune diseases.
  • Both IL-12 and IL-23 have the structure of the p40 protein domain.
  • the monoclonal antibody that specifically binds to the p40 protein domain can act as a blocker of the IL-12 and IL-23 pathways, thereby becoming an autoimmune disease (such as plaque). Psoriasis, systemic lupus erythematosus, etc.) is a new drug for the treatment of.
  • ulcerative colitis is mainly a disease of the body's immune dysfunction. Its clinical and pathological changes are complex, the course of the disease is long, and it is often recurrent. It is a relatively complex immune disease, and more than half of the patients All received conventional or biological therapy and did not get any relief. Ulcerative colitis is the result of a combination of exogenous factors and host factors under a certain genetic background. The lesions are mostly located in the sigmoid colon and rectum, but can also extend to the descending colon or even the entire colon. The course of the disease is long, often recurrent. This disease is seen at any age, but it is most common between 20 and 30 years old. In view of the characteristics of ulcerative colitis, it is necessary to find more excellent antibody drugs to treat patients with ulcerative colitis.
  • the inventors Based on the crystal structure of IL-12/IL-23 p40, the inventors used artificial intelligence to design monoclonal antibody technology to develop antibody sequences, and conducted preliminary screening of antibodies by ELISA and other methods, and finally selected antibodies with better titer as candidates The antibody undergoes subsequent pharmacodynamic studies.
  • humanized antibodies against human IL-12/IL-23 p40 protein domain for example, humanized antibodies named H5L9, H5L10, H5L11, H5L12, H5L14, H8L15).
  • the present inventors surprisingly found that the antibody of the present invention can effectively block the binding of human IL-12/IL-23 p40 protein domain to cell surface receptors IL-12R ⁇ 1 and IL-23R, and inhibit the binding of IL-23 The induced human peripheral blood mononuclear lymphocytes secrete IL-17A.
  • the present inventors also surprisingly found that the antibody of the present invention can effectively bind to human IL-12/IL-23 p40 protein domain and block human IL-12/IL-23 p40 protein domain and its ligands IL-12R ⁇ 1 and IL-23R
  • the combination of IL-12/IL-23 inhibits the activation of the downstream signaling pathways of IL-12/IL-23; it can be used to prevent and treat autoimmune diseases (such as plaque psoriasis, systemic lupus erythematosus, etc.) and ulcerative colitis (such as difficult Therapeutic or recurrent) drug potential.
  • autoimmune diseases such as plaque psoriasis, systemic lupus erythematosus, etc.
  • ulcerative colitis such as difficult Therapeutic or recurrent
  • amino acid sequence of the CDR region of the above antibody sequence is analyzed by technical means well known to those skilled in the art, for example, the VBASE2 database.
  • the CDR region of an antibody is responsible for the binding specificity of the antibody to the antigen.
  • AbM numbering system The definition of AbM CDR comes from Martin's related research (Martin ACR, Cheetham JC, Rees AR (1989) Modelling antibody hypervariable loops: A combined algorithm. Proc Natl Acad Sci USA 86: 9268-9272). The definition method integrates the partial definitions of Kabat and Chothia.
  • Kabat numbering system see, for example, Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991.
  • Chothia numbering system see, for example, Chothia & Lesk (1987) J. Mol. Biol. 196:901-917; Chothia et al. (1989) Nature 342:878-883.
  • IMGT numbering system see, for example, Lefanc et al., Dev.Comparat.Immunol.27:55-77, 2003.
  • the antibodies H5L9, H5L10, H5L11, H5L12, H5L14 of the present invention have the same HCDR1-3:
  • amino acid sequences of the three HCDR regions of the heavy chain variable region are as follows:
  • HCDR1 GYSFTTYW (SEQ ID NO: 3)
  • HCDR2 IMSPVDSDI (SEQ ID NO: 4)
  • HCDR3 ARRRPGQGYFDF (SEQ ID NO: 5)
  • the antibody H5L9 of the present invention has LCDR1-3:
  • amino acid sequences of the 3 CDR regions of the light chain variable region are as follows:
  • LCDR1 QNVGSW (SEQ ID NO: 8)
  • LCDR2 ASS (SEQ ID NO: 9)
  • LCDR3 QQYDIYPFT (SEQ ID NO: 10)
  • the antibody H5L10 of the present invention has LCDR1-3:
  • amino acid sequences of the 3 CDR regions of the light chain variable region are as follows:
  • LCDR1 QSVGSW (SEQ ID NO: 19)
  • LCDR2 ASN (SEQ ID NO: 21)
  • LCDR3 QQYNIYPYT (SEQ ID NO: 22)
  • the antibodies H5L11 and H5L12 of the present invention have the same LCDR1-3:
  • amino acid sequences of the 3 CDR regions of the light chain variable region are as follows:
  • LCDR1 QSVSSW (SEQ ID NO: 20)
  • LCDR2 ASN (SEQ ID NO: 21)
  • LCDR3 QQYNIYPYT (SEQ ID NO: 22)
  • the antibody H5L14 of the present invention has LCDR1-3:
  • amino acid sequences of the 3 CDR regions of the light chain variable region are as follows:
  • LCDR1 QSVSSW (SEQ ID NO: 20)
  • LCDR2 ASN (SEQ ID NO: 21)
  • LCDR3 QQYNIYPFT (SEQ ID NO: 23)
  • the antibody H8L15 of the present invention has HCDR1-3 and LCDR1-3:
  • amino acid sequences of the three HCDR regions of the heavy chain variable region are as follows:
  • HCDR1 GYTFTSYW (SEQ ID NO: 26)
  • HCDR2 MSPVDSDI (SEQ ID NO: 4)
  • HCDR3 ARRRPGQGYFDF (SEQ ID NO: 5)
  • amino acid sequences of the 3 CDR regions of the light chain variable region are as follows:
  • LCDR1 QSVGTW (SEQ ID NO: 27)
  • LCDR2 AAS (SEQ ID NO: 28)
  • LCDR3 QQYNIYPYT (SEQ ID NO: 22).
  • One aspect of the present invention relates to antibodies or antigen-binding fragments thereof, preferably specifically binding to human IL-12/IL-23 p40, wherein:
  • the antibody comprises:
  • the heavy chain variable region shown in SEQ ID NO: 1 comprises HCDR1, HCDR2 and HCDR3, preferably HCDR1 comprises the sequence shown in SEQ ID NO: 3, which has at least 80%, 81%, 82% of the sequence, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or A sequence with 99% sequence identity, or an amino acid sequence with one or more (preferably 1, 2, or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared with the said sequence, or consisting of , HCDR2 includes the sequence shown in SEQ ID NO: 4, which has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90% of the sequence.
  • % preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity, or a sequence with one or more (preferably 1, 2, or 3) the amino acid sequence of conservative amino acid mutations (preferably substitutions, insertions or deletions), or consisting of them, and
  • HCDR3 includes the sequence shown in SEQ ID NO: 5, which has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90% of the sequence. , Preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity, or have one or more sequences (preferably 1 One, two or three) amino acid sequence of conservative amino acid mutations (preferably substitutions, insertions or deletions), or consisting of them, and the antibody further comprises:
  • the light chain variable region shown in SEQ ID NO: 6 includes LCDR1, LCDR2 and LCDR.
  • LCDR1 includes the amino acid shown in SEQ ID NO: 8, or at least 80%, 81%, 82% of the sequence. %, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98 % Or 99% sequence identity, or an amino acid sequence with one or more (preferably 1, 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared with the said sequence, or Its composition, LCDR2 includes the amino acid sequence shown in SEQ ID NO: 9, which has at least 80%, 81%, 82%, 83%, 84%, 85%, 90%, preferably at least 91%, 92% with the sequence.
  • LCDR3 contains the sequence shown in SEQ ID NO: 10, which has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90% of the sequence. , Preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity, or have one or more sequences (preferably 1 One, two or three) amino acid sequence of conservative amino acid mutation (preferably substitution, insertion or deletion), or consisting of it.
  • the antibody includes:
  • the heavy chain variable region shown in SEQ ID NO: 1 includes LCDR1, LCDR2 and LCDR.
  • HCDR1 includes the sequence shown in SEQ ID NO: 3, which is at least 80%, 81%, 82% of the sequence. , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% Or a sequence with 99% sequence identity, or an amino acid sequence with one or more (preferably 1, 2, or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared with the said sequence, or Composition
  • HCDR2 includes the sequence shown in SEQ ID NO: 4, which has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% of the sequence.
  • sequence identity sequence preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity sequence, or compared with the sequence has one or more ( Preferably 1, 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) of amino acid sequences, or consisting of them, and
  • HCDR3 includes the sequence shown in SEQ ID NO: 5, which has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90% of the sequence. , Preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity, or have one or more sequences (preferably 1 One, two or three) amino acid sequence of conservative amino acid mutations (preferably substitutions, insertions or deletions), or consisting of them, and the antibody further comprises:
  • the light chain variable region shown in SEQ ID NO: 11 includes LCDR1, LCDR2 and LCDR.
  • LCDR1 includes the amino acid shown in SEQ ID NO: 19, or has at least 80%, 81%, 82% of the sequence. %, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98 % Or 99% sequence identity, or an amino acid sequence with one or more (preferably 1, 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared with the said sequence, or Its composition,
  • LCDR2 contains the amino acid sequence shown in SEQ ID NO: 21, which has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90% of the sequence. %, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity, or a sequence with one or more (preferably 1, 2, or 3) the amino acid sequence of conservative amino acid mutations (preferably substitutions, insertions or deletions), or consisting of them, and
  • LCDR3 contains the sequence shown in SEQ ID NO: 22, which has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90% of the sequence. , Preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity, or have one or more sequences (preferably 1 One, two or three) amino acid sequence of conservative amino acid mutation (preferably substitution, insertion or deletion), or consisting of it.
  • the antibody comprises:
  • the heavy chain variable region shown in SEQ ID NO: 1 includes LCDR1, LCDR2 and LCDR.
  • HCDR1 includes the sequence shown in SEQ ID NO: 3, which is at least 80%, 81%, 82% of the sequence. , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% Or a sequence with 99% sequence identity, or an amino acid sequence with one or more (preferably 1, 2, or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared with the said sequence, or Composition
  • HCDR2 includes the sequence shown in SEQ ID NO: 4, which has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% of the sequence.
  • sequence identity sequence preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity sequence, or compared with the sequence has one or more ( Preferably 1, 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) of amino acid sequences, or consisting of them, and
  • HCDR3 includes the sequence shown in SEQ ID NO: 5, which has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90% of the sequence. , Preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity, or have one or more sequences (preferably 1 One, two or three) amino acid sequence of conservative amino acid mutations (preferably substitutions, insertions or deletions), or consisting of them, and the antibody further comprises:
  • the light chain variable region shown in SEQ ID NO: 13, 15 includes LCDR1, LCDR2 and LCDR.
  • LCDR1 includes the amino acid shown in SEQ ID NO: 20, or has at least 80%, 81% of the sequence. , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97% , A sequence with 98% or 99% sequence identity, or an amino acid sequence with one or more (preferably 1, 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared with the said sequence, Or consist of it,
  • LCDR2 contains the amino acid sequence shown in SEQ ID NO: 21, which has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90% of the sequence. %, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity, or a sequence with one or more (preferably 1, 2, or 3) the amino acid sequence of conservative amino acid mutations (preferably substitutions, insertions or deletions), or consisting of them, and
  • LCDR3 contains the sequence shown in SEQ ID NO: 22, which has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90% of the sequence. , Preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity, or have one or more sequences (preferably 1 One, two or three) amino acid sequence of conservative amino acid mutation (preferably substitution, insertion or deletion), or consisting of it.
  • the antibody comprises:
  • the heavy chain variable region shown in SEQ ID NO: 1 includes LCDR1, LCDR2 and LCDR.
  • HCDR1 includes the sequence shown in SEQ ID NO: 3, which is at least 80%, 81%, 82% of the sequence. , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% Or a sequence with 99% sequence identity, or an amino acid sequence with one or more (preferably 1, 2, or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared with the said sequence, or Composition
  • HCDR2 includes the sequence shown in SEQ ID NO: 4, which has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% of the sequence.
  • sequence identity sequence preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity sequence, or compared with the sequence has one or more ( Preferably 1, 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) of amino acid sequences, or consisting of them, and
  • HCDR3 includes the sequence shown in SEQ ID NO: 5, which has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90% of the sequence. , Preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity, or have one or more sequences (preferably 1 One, two or three) amino acid sequence of conservative amino acid mutations (preferably substitutions, insertions or deletions), or consisting of them, and the antibody further comprises:
  • the light chain variable region shown in SEQ ID NO: 17 includes LCDR1, LCDR2 and LCDR.
  • LCDR1 includes the amino acid shown in SEQ ID NO: 20, or has at least 80%, 81%, 82% of the sequence. %, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98 % Or 99% sequence identity, or an amino acid sequence with one or more (preferably 1, 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared with the said sequence, or Its composition,
  • LCDR2 contains the amino acid sequence shown in SEQ ID NO: 21, which has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90% of the sequence. %, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity, or a sequence with one or more (preferably 1, 2, or 3) the amino acid sequence of conservative amino acid mutations (preferably substitutions, insertions or deletions), or consisting of them, and
  • LCDR3 contains the sequence shown in SEQ ID NO: 23, which has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90% of the sequence. , Preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity, or have one or more sequences (preferably 1 One, two or three) amino acid sequence of conservative amino acid mutation (preferably substitution, insertion or deletion), or consisting of it.
  • the antibody comprises:
  • the heavy chain variable region shown in SEQ ID NO: 24 includes LCDR1, LCDR2 and LCDR.
  • HCDR1 includes the sequence shown in SEQ ID NO: 26, which has at least 80%, 81%, 82% of the sequence. , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% Or a sequence with 99% sequence identity, or an amino acid sequence with one or more (preferably 1, 2, or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared with the said sequence, or Composition
  • HCDR2 includes the sequence shown in SEQ ID NO: 4, which has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% of the sequence.
  • sequence identity sequence preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity sequence, or compared with the sequence has one or more ( Preferably 1, 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) of amino acid sequences, or consisting of them, and
  • HCDR3 includes the sequence shown in SEQ ID NO: 5, which has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90% of the sequence. , Preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity, or have one or more sequences (preferably 1 One, two or three) amino acid sequence of conservative amino acid mutations (preferably substitutions, insertions or deletions), or consisting of them, and the antibody further comprises:
  • the light chain variable region shown in SEQ ID NO: 25 includes LCDR1, LCDR2 and LCDR.
  • LCDR1 includes the amino acid shown in SEQ ID NO: 27, or has at least 80%, 81%, 82% of the sequence. %, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98 % Or 99% sequence identity, or an amino acid sequence with one or more (preferably 1, 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared with the said sequence, or Its composition,
  • LCDR2 includes the amino acid sequence shown in SEQ ID NO: 28, which has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90% of the sequence. %, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity, or a sequence with one or more (preferably 1, 2, or 3) the amino acid sequence of conservative amino acid mutations (preferably substitutions, insertions or deletions), or consisting of them, and
  • LCDR3 contains the sequence shown in SEQ ID NO: 22, which has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90% of the sequence. , Preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity, or have one or more sequences (preferably 1 One, two or three) amino acid sequence of conservative amino acid mutation (preferably substitution, insertion or deletion), or consisting of it.
  • the antibody includes:
  • the heavy chain variable region which contains or consists of the following sequence:
  • SEQ ID NO: the amino acid sequence shown in 1, or
  • sequence shown in SEQ ID NO: 1 has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity sequence, or
  • amino acid sequence shown in SEQ ID NO: 1 there are one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitution, insertion or Missing) amino acid sequence, and
  • the light chain variable region which comprises or consists of the following sequence:
  • SEQ ID NO: the amino acid sequence shown in 6, or
  • sequence shown in SEQ ID NO: 6 has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity sequence, or
  • amino acid sequence shown in SEQ ID NO: 6 there are one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or Missing) amino acid sequence.
  • SEQ ID NO: the amino acid sequence shown in 1, or
  • sequence shown in SEQ ID NO: 1 has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity sequence, or
  • amino acid sequence shown in SEQ ID NO: 1 there are one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitution, insertion or Missing) amino acid sequence, and
  • the light chain variable region which comprises or consists of the following sequence:
  • SEQ ID NO: the amino acid sequence shown in 11, or
  • sequence shown in SEQ ID NO: 11 has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity sequence, or
  • amino acid sequence shown in SEQ ID NO: 11 Compared with the amino acid sequence shown in SEQ ID NO: 11, it has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or Missing) amino acid sequence.
  • SEQ ID NO: the amino acid sequence shown in 1, or
  • sequence shown in SEQ ID NO: 1 has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity sequence, or
  • amino acid sequence shown in SEQ ID NO: 1 there are one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitution, insertion or Missing) amino acid sequence, and
  • the light chain variable region which comprises or consists of the following sequence:
  • SEQ ID NO: the amino acid sequence shown in 13, or
  • sequence shown in SEQ ID NO: 13 has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity sequence, or
  • amino acid sequence shown in SEQ ID NO: 13 there are one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or Missing) amino acid sequence.
  • the heavy chain variable region which comprises or consists of the following sequence:
  • SEQ ID NO: the amino acid sequence shown in 1, or
  • sequence shown in SEQ ID NO: 1 has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity sequence, or
  • amino acid sequence shown in SEQ ID NO: 1 there are one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitution, insertion or Missing) amino acid sequence, and
  • the light chain variable region which comprises or consists of the following sequence:
  • sequence shown in SEQ ID NO: 15 has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity sequence, or
  • amino acid sequence shown in SEQ ID NO: 15 there are one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitution, insertion or Missing) amino acid sequence.
  • the heavy chain variable region which contains or consists of the following sequence:
  • SEQ ID NO: the amino acid sequence shown in 1, or
  • sequence shown in SEQ ID NO: 1 has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity sequence, or
  • amino acid sequence shown in SEQ ID NO: 1 there are one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitution, insertion or Missing) amino acid sequence, and
  • the light chain variable region which comprises or consists of the following sequence:
  • SEQ ID NO: the amino acid sequence shown in 17, or
  • sequence shown in SEQ ID NO: 17 has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity sequence, or
  • amino acid sequence shown in SEQ ID NO: 17 there are one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or Missing) amino acid sequence.
  • the heavy chain variable region which contains or consists of the following sequence:
  • SEQ ID NO: the amino acid sequence shown in 24, or
  • sequence shown in SEQ ID NO: 24 has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity sequence, or
  • amino acid sequence shown in SEQ ID NO: 24 it has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or Missing) amino acid sequence, and
  • the light chain variable region which comprises or consists of the following sequence:
  • sequence shown in SEQ ID NO: 25 has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity sequence, or
  • amino acid sequence shown in SEQ ID NO: 25 Compared with the amino acid sequence shown in SEQ ID NO: 25, it has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or Missing) amino acid sequence.
  • the antibody further comprises the framework region FR of the variable region of the heavy chain.
  • the framework region FR comprises FR-H1, FR-H2, FR-H3 and FR-H4, wherein FR -H1 contains the amino acid sequence of SEQ ID NO: 29, or has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88 with the sequence shown in SEQ ID NO: 29 %, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity, or a sequence with SEQ ID NO: 29
  • the amino acid sequence shown has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid sequences with conservative amino acid mutations (preferably substitutions, insertions or deletions), or Consists of its columns;
  • FR-H2 contains the amino acid sequence of SEQ ID NO: 30 or has at least 80%, 81%, 82%, 83%
  • FR-H4 includes the amino acid sequence of SEQ ID NO: 32, or has at least 80%, 81%, 82%, 83% with the sequence shown in SEQ ID NO: 32 , 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% A sequence of sequence identity, or one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conserved amino acids compared with the amino acid sequence shown in SEQ ID NO: 32 The amino acid
  • the antibody further comprises the framework region FR of the light chain variable region.
  • the framework region FR comprises FR-L1, FR-L2, FR-L3 and FR-L4, where FR -L1 contains the amino acid sequence of SEQ ID NO: 33 or has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88% with the sequence shown in SEQ ID NO: 33 , 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity, or a sequence with SEQ ID NO: 33
  • the amino acid sequence of has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid sequences with conservative amino acid mutations (preferably substitutions, insertions or deletions), or by Its composition;
  • FR-L2 includes the amino acid sequence of SEQ ID NO: 34 or has at least 80%, 81%, 82%, 83%, 84%, 85%
  • the antibody further comprises the framework region FR of the light chain variable region.
  • the framework region FR comprises FR-L1, FR-L2, FR-L3 and FR-L4, where FR -L1 contains the amino acid sequence of SEQ ID NO: 41 or has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88% with the sequence shown in SEQ ID NO: 41 , 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity, or a sequence with SEQ ID NO: 41
  • the amino acid sequence of has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid sequences with conservative amino acid mutations (preferably substitutions, insertions or deletions), or by Its composition;
  • FR-L2 includes the amino acid sequence of SEQ ID NO: 42 or has at least 80%, 81%, 82%, 83%, 84%, 85%
  • the antibody further comprises the framework region FR of the light chain variable region.
  • the framework region FR comprises FR-L1, FR-L2, FR-L3 and FR-L4, where FR -L1 contains the amino acid sequence of SEQ ID NO: 33 or has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88% of the sequence shown in SEQ ID NO: 33 , 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity, or a sequence with SEQ ID NO: 33
  • the amino acid sequence of has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid sequences with conservative amino acid mutations (preferably substitutions, insertions or deletions), or by Its composition;
  • FR-L2 includes the amino acid sequence of SEQ ID NO: 45 or has at least 80%, 81%, 82%, 83%, 84%, 85%
  • the antibody further comprises the framework region FR of the light chain variable region.
  • the framework region FR comprises FR-L1, FR-L2, FR-L3 and FR-L4, where FR -L1 contains the amino acid sequence of SEQ ID NO: 33 or has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88% with the sequence shown in SEQ ID NO: 33 , 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity, or a sequence with SEQ ID NO: 33 Compared with the amino acid sequence, the amino acid sequence has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitution, insertion or deletion) amino acid sequence, or Its composition; FR-L2 includes the amino acid sequence of SEQ ID NO: 47 or has at least 80%, 81%, 82%, 83%, 84%,
  • the antibody further comprises the framework region FR of the light chain variable region.
  • the framework region FR comprises FR-L1, FR-L2, FR-L3 and FR-L4, where FR -L1 contains the amino acid sequence of SEQ ID NO: 33 or has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88% with the sequence shown in SEQ ID NO: 33 , 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity, or a sequence with SEQ ID NO: 33
  • the amino acid sequence of has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid sequences with conservative amino acid mutations (preferably substitutions, insertions or deletions), or by Its composition;
  • FR-L2 includes the amino acid sequence of SEQ ID NO: 45 or has at least 80%, 81%, 82%, 83%, 84%, 85%
  • the antibody comprises the heavy chain shown in SEQ ID NO: 39 and the light chain shown in SEQ ID NO: 40, or the heavy chain shown in SEQ ID NO: 39 and SEQ ID NO :The light chain composition shown by 40.
  • the antibody comprises the heavy chain shown in SEQ ID NO: 49 and the light chain shown in SEQ ID NO: 50, or the heavy chain shown in SEQ ID NO: 49 and SEQ ID NO :The light chain composition shown by 50.
  • the antibody comprises the heavy chain shown in SEQ ID NO: 49 and the light chain shown in SEQ ID NO: 51, or the heavy chain shown in SEQ ID NO: 49 and SEQ ID NO :The light chain composition shown at 51.
  • the antibody comprises the heavy chain shown in SEQ ID NO: 49 and the light chain shown in SEQ ID NO: 52, or the heavy chain shown in SEQ ID NO: 49 and SEQ ID NO :The light chain composition shown in 52.
  • the antibody comprises the heavy chain shown in SEQ ID NO: 49 and the light chain shown in SEQ ID NO: 53, or the heavy chain shown in SEQ ID NO: 49 and SEQ ID NO :The light chain composition shown in 53.
  • the antibody comprises the heavy chain shown in SEQ ID NO: 49 and the light chain shown in SEQ ID NO: 54 or the heavy chain shown in SEQ ID NO: 49 and SEQ ID NO :The light chain composition shown in 54.
  • polypeptide comprising the sequence shown in SEQ ID NO: 3, 4 and 5, wherein the polypeptide is part of an antibody against the human IL-12/IL-23 p40 protein domain, Specifically binding to the human IL-12/IL-23 p40 protein domain, the antibody also contains the sequences shown in SEQ ID NOs: 8, 9 and 10.
  • polypeptide comprising the sequence shown in SEQ ID NO: 8, 9 and 10, wherein the polypeptide is part of an antibody against the human IL-12/IL-23 p40 protein domain, Specifically binding to the human IL-12/IL-23 p40 protein domain, the antibody also includes the sequences shown in SEQ ID NOs: 3, 4 and 5.
  • the present invention relates to an isolated polypeptide comprising the sequence shown in SEQ ID NO: 3, 4 and 5, wherein the polypeptide is part of an antibody against the human IL-12/IL-23 p40 protein domain, Specifically binding to the human IL-12/IL-23 p40 protein domain, the antibody also includes the sequences shown in SEQ ID NOs: 19, 21 and 22.
  • polypeptide comprising the sequence shown in SEQ ID NO: 19, 21 and 22, wherein the polypeptide is part of an antibody against human IL-12/IL-23 p40 protein domain, Specifically binding to the human IL-12/IL-23 p40 protein domain, the antibody also includes the sequences shown in SEQ ID NOs: 3, 4 and 5.
  • the present invention relates to an isolated polypeptide comprising the sequence shown in SEQ ID NO: 3, 4 and 5, wherein the polypeptide is part of an antibody against the human IL-12/IL-23 p40 protein domain, Specifically binding to the human IL-12/IL-23 p40 protein domain, the antibody also includes the sequences shown in SEQ ID NOs: 20, 21 and 22.
  • the present invention relates to an isolated polypeptide comprising the sequence shown in SEQ ID NO: 20, 21 and 22, wherein the polypeptide is part of an antibody against the human IL-12/IL-23 p40 protein domain, Specifically binding to the human IL-12/IL-23 p40 protein domain, the antibody also includes the sequences shown in SEQ ID NOs: 3, 4 and 5.
  • the present invention relates to an isolated polypeptide comprising the sequence shown in SEQ ID NO: 3, 4 and 5, wherein the polypeptide is part of an antibody against the human IL-12/IL-23 p40 protein domain, Specifically binding to the human IL-12/IL-23 p40 protein domain, the antibody also includes the sequences shown in SEQ ID NOs: 20, 21 and 23.
  • polypeptide comprising the sequence shown in SEQ ID NO: 20, 21 and 23, wherein the polypeptide is part of an antibody against human IL-12/IL-23 p40 protein domain, Specifically binding to the human IL-12/IL-23 p40 protein domain, the antibody also includes the sequences shown in SEQ ID NOs: 3, 4 and 5.
  • polypeptide comprising the sequence shown in SEQ ID NO: 26, 4 and 5, wherein the polypeptide is part of an antibody against the human IL-12/IL-23 p40 protein domain, Specifically binding to the human IL-12/IL-23 p40 protein domain, the antibody also contains the sequences shown in SEQ ID NOs: 27, 28 and 22.
  • polypeptide comprising the sequence shown in SEQ ID NO: 27, 28 and 22, wherein the polypeptide is part of an antibody against human IL-12/IL-23 p40 protein domain, Specifically binding to the human IL-12/IL-23 p40 protein domain, the antibody also includes the sequences shown in SEQ ID NOs: 26, 4 and 5.
  • an isolated polypeptide which comprises the sequence shown in SEQ ID NO: 1 or 24 or has at least 80%, 81%, 82%, 83%, 84%, 85% with said sequence, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity sequence, or An amino acid sequence with one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the sequence, wherein The polypeptide is part of an antibody against human IL-12/IL-23 p40 protein domain, and specifically binds to human IL-12/IL-23 p40 protein domain, and the antibody also includes SEQ ID NOs: 6, 11, 13 , 15, 17 or 25 or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90% of the sequence shown
  • polypeptide which comprises the sequence shown in SEQ ID NO: 6, 11, 13, 15, 17 or 25 or has at least 80%, 81%, 82%, 83%, 84%, 85% with said sequence , 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity, Or an amino acid sequence with one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the sequence,
  • the polypeptide is part of an antibody against the human IL-12/IL-23 p40 protein domain and specifically binds to the human IL-12/IL-23 p40 protein domain, and the antibody further comprises SEQ ID NO: 1 or 24.
  • the antigen-binding fragment is selected from Fab, Fab', F(ab') 2 , Fd, Fv, dAb, Fab/c, complementarity determining region (CDR) fragments, single-chain antibodies (e.g. , ScFv), bivalent antibodies, domain antibodies.
  • CDR complementarity determining region
  • the antibody is a humanized antibody, a chimeric antibody, a multispecific antibody (e.g., a bispecific antibody).
  • the antibody is less than about 10 -5 M, such as less than about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, or 10 -10 M or less K D binds to human IL-12/IL-23 p40 protein domain.
  • the K D is measured by a Fortebio molecular interaction instrument.
  • the antibody is less than about 100 nM, such as less than about 10 nM, 1 nM, 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, 0.1 nM or
  • the smaller EC50 binds to human IL-12/IL-23 p40 protein domain. Specifically, the EC50 is measured by an indirect ELISA method.
  • the antibody includes a constant region, and the constant region is from a species other than murine, such as from a human antibody, preferably from human IgG, more preferably IgG1.
  • the constant region of the antibody is humanized, for example, the heavy chain constant region uses Ig gamma-1 chain C region, more preferably the Iggamma-1 chain with GenBank registration number ACCESSION: P01857 C region: Ig kappa chain C region is used for the light chain constant region, more preferably the Ig kappa chain C region with the GenBank registration number ACCESSION: P01834.
  • Another aspect of the present invention relates to an isolated polynucleotide encoding a polypeptide comprising the sequence shown in SEQ ID NO: 3, 4 and 5, wherein the polypeptide acts as an anti-human IL-12/IL-23 p40 protein A part of the antibody of the domain specifically binds to the human IL-12/IL-23 p40 protein domain.
  • the antibody also contains the sequences shown in SEQ ID NOs: 8, 9 and 10.
  • the present invention relates to an isolated polynucleotide encoding a polypeptide comprising the sequence shown in SEQ ID NO: 8, 9 and 10, wherein the polypeptide functions as an anti-human IL-12/IL-23 p40
  • a part of the antibody of the protein domain specifically binds to the human IL-12/IL-23 p40 protein domain, and the antibody also contains the sequences shown in SEQ ID NOs: 3, 4 and 5.
  • Another aspect of the present invention relates to an isolated polynucleotide encoding a polypeptide comprising the sequence shown in SEQ ID NO: 3, 4 and 5, wherein the polypeptide acts as an anti-human IL-12/IL-23 p40 protein
  • a part of the antibody of the domain specifically binds to the human IL-12/IL-23 p40 protein domain, and the antibody also contains the sequences shown in SEQ ID NOs: 19, 21 and 22.
  • the present invention relates to an isolated polynucleotide encoding a polypeptide comprising the sequence shown in SEQ ID NOs: 19, 21 and 22, wherein the polypeptide functions as an anti-human IL-12/IL-23 p40
  • a part of the antibody of the protein domain specifically binds to the human IL-12/IL-23 p40 protein domain, and the antibody also contains the sequences shown in SEQ ID NOs: 3, 4 and 5.
  • Another aspect of the present invention relates to an isolated polynucleotide encoding a polypeptide comprising the sequence shown in SEQ ID NO: 3, 4 and 5, wherein the polypeptide acts as an anti-human IL-12/IL-23 p40 protein
  • a part of the antibody of the domain specifically binds to the human IL-12/IL-23 p40 protein domain, and the antibody also contains the sequences shown in SEQ ID NOs: 20, 21 and 22.
  • polypeptide comprising the sequence shown in SEQ ID NOs: 20, 21 and 22, wherein the polypeptide functions as an anti-human IL-12/IL-23 p40
  • a part of the antibody of the protein domain specifically binds to the human IL-12/IL-23 p40 protein domain, and the antibody also contains the sequences shown in SEQ ID NOs: 3, 4 and 5.
  • Another aspect of the present invention relates to an isolated polynucleotide encoding a polypeptide comprising the sequence shown in SEQ ID NO: 3, 4 and 5, wherein the polypeptide acts as an anti-human IL-12/IL-23 p40 protein
  • a part of the antibody of the domain specifically binds to the human IL-12/IL-23 p40 protein domain, and the antibody also contains the sequences shown in SEQ ID NOs: 20, 21 and 23.
  • the present invention relates to an isolated polynucleotide encoding a polypeptide comprising the sequence shown in SEQ ID NOs: 20, 21 and 23, wherein the polypeptide functions as an anti-human IL-12/IL-23 p40 A part of the antibody of the protein domain specifically binds to the human IL-12/IL-23 p40 protein domain, and the antibody also contains the sequences shown in SEQ ID NOs: 3, 4 and 5.
  • Another aspect of the present invention relates to an isolated polynucleotide encoding a polypeptide comprising the sequence shown in SEQ ID NO: 26, 4 and 5, wherein the polypeptide acts as an anti-human IL-12/IL-23 p40 protein A part of the antibody of the domain specifically binds to the human IL-12/IL-23 p40 protein domain.
  • the antibody also contains the sequences shown in SEQ ID NOs: 27, 28 and 22.
  • the present invention relates to an isolated polynucleotide encoding a polypeptide comprising the sequence shown in SEQ ID NOs: 27, 28 and 22, wherein the polypeptide functions as an anti-human IL-12/IL-23 p40
  • a part of the antibody of the protein domain specifically binds to the human IL-12/IL-23 p40 protein domain, and the antibody also includes the sequence shown in SEQ ID NO: 26, 4 and 5.
  • polypeptide comprising the sequence shown in SEQ ID NO: 1 or 24 or at least 80%, 81%, 82%, 83% of the sequence , 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%
  • a sequence of sequence identity, or one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or Deletion) wherein the polypeptide is part of an antibody against human IL-12/IL-23 p40 protein domain and specifically binds to human IL-12/IL-23 p40 protein domain, and the antibody further comprises SEQ ID NO: The sequence shown by 6, 11, 13, 15, 17 or 25 or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88% of the sequence , 8
  • polypeptide comprising the sequence shown in SEQ ID NO: 6, 11, 13, 15, 17 or 25 or at least 80%, 81%, 82%, 83 %, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % Sequence identity sequence, or one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions) compared to the sequence Or deleted), wherein the polypeptide is part of an antibody against human IL-12/IL-23 p40 protein domain and specifically binds to human IL-12/IL-23 p40 protein domain, and the antibody further comprises SEQ ID NO: The sequence shown by 1 or 24 or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90% of the sequence shown in SEQ ID NO: 6, 11, 13, 15, 17 or 25 or at least 80%, 8
  • the polynucleotide comprises or consists of the following sequence: the nucleotide sequence shown in SEQ ID NO: 2, or at least 80%, 81%, 82%, 83% of the sequence , 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% Sequence of sequence identity.
  • the polynucleotide comprises or consists of the following sequence: the nucleotide sequence shown in SEQ ID NO: 7 or at least 80%, 81%, 82%, 83% of the sequence, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence Sequence of identity.
  • the polynucleotide comprises or consists of the following sequence: the nucleotide sequence shown in SEQ ID NO: 12, or at least 80%, 81%, 82%, 83% of the sequence , 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% Sequence of sequence identity.
  • the polynucleotide comprises the following sequence or consists of the following sequence: the nucleotide sequence shown in SEQ ID NO: 14 or at least 80%, 81%, 82%, 83% with the sequence, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence Sequence of identity.
  • the polynucleotide comprises the following sequence or consists of the following sequence: the nucleotide sequence shown in SEQ ID NO: 16, or at least 80%, 81%, 82%, 83% with the sequence , 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% Sequence of sequence identity.
  • the polynucleotide comprises or consists of the following sequence: the nucleotide sequence shown in SEQ ID NO: 18 or at least 80%, 81%, 82%, 83% of the sequence, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence Sequence of identity.
  • the polynucleotide comprises the following sequence or consists of the following sequence: the nucleotide sequence shown in SEQ ID NO: 37, or at least 80%, 81%, 82%, 83% with the sequence , 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% Sequence of sequence identity.
  • the polynucleotide comprises or consists of the following sequence: the nucleotide sequence shown in SEQ ID NO: 38 or at least 80%, 81%, 82%, 83% with the sequence, 84%, 85%, 86%, 87%, 88%, 89%, 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence Sequence of identity.
  • Yet another aspect of the present invention relates to a vector, which comprises any one of the polynucleotides described above in the present invention.
  • Another aspect of the present invention relates to a host cell, which comprises the polynucleotide of any one of the above-mentioned in the present invention, or the vector of the present invention.
  • Another aspect of the present invention relates to a method for preparing the antibody or antigen-binding fragment thereof of any one of the above of the present invention, which comprises culturing the host cell of the present invention under suitable conditions, and recovering all the antibodies from the cell culture. The steps of the antibody or antigen-binding fragment thereof.
  • an antibody conjugate which includes the anti-human IL-12/IL-23 p40 protein domain antibody or an antigen-binding fragment thereof, and a coupling part conjugated therewith.
  • the coupling part is a purification tag (such as His tag), a cytotoxic agent, or a detectable label.
  • the coupling part is a radioisotope, a luminescent substance, a colored substance, an enzyme or polyethylene glycol.
  • a fusion protein which includes the antibody against the human IL-12/IL-23 p40 protein domain or an antigen-binding fragment thereof as described above.
  • a multispecific antibody preferably a bispecific antibody, which comprises the antibody of the present invention or an antigen-binding fragment thereof.
  • kits which includes the antibody or antigen-binding fragment thereof, the antibody conjugate, fusion protein or multispecific antibody of the present invention as described above.
  • the kit further includes a second antibody, which specifically recognizes the antibody or antigen-binding fragment thereof; optionally, the second antibody also includes a detectable label, such as a radioisotope, a luminescent substance, a colored Substance, enzyme or polyethylene glycol.
  • a detectable label such as a radioisotope, a luminescent substance, a colored Substance, enzyme or polyethylene glycol.
  • Another aspect of the present invention relates to the use of the antibody or antigen-binding fragment, antibody conjugate, fusion protein or multispecific antibody of any one of the above-mentioned antibodies of the present invention in the preparation of a kit for detection The presence or level of human IL-12/IL-23 p40 in the sample.
  • Another aspect of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising the antibody or antigen-binding fragment, antibody conjugate, multispecific antibody or fusion protein of any one of the above in the present invention; optionally, it It also includes pharmaceutically acceptable carriers and/or excipients.
  • Another aspect of the present invention relates to the use of any one of the antibodies or antigen-binding fragments, antibody conjugates, multispecific antibodies, fusion proteins or pharmaceutical compositions described above in the preparation of the following drugs:
  • Drugs that block the activity of human IL-12/IL-23 p40 or down-regulate its level or
  • the ligand of human IL-12/IL-23 p40 is human IL-12R ⁇ 1 or human IL-23R.
  • the present invention relates to the use of any one of the antibodies or antigen-binding fragments, antibody conjugates, multispecific antibodies, fusion proteins or pharmaceutical compositions described above in the preparation of drugs for treating diseases selected from: Autoimmune diseases (such as plaque psoriasis, systemic lupus erythematosus) or ulcerative colitis (such as refractory or relapsed).
  • Autoimmune diseases such as plaque psoriasis, systemic lupus erythematosus
  • ulcerative colitis such as refractory or relapsed.
  • Another aspect of the present invention relates to an in vivo or in vitro method, including the step of applying cells containing the antibody or antigen-binding fragment, antibody conjugate, multispecific antibody, fusion protein or pharmaceutical composition of the present invention , Or the step of administering to a subject in need an effective amount of the antibody or antigen-binding fragment, antibody conjugate, multispecific antibody, fusion protein or pharmaceutical composition of any of the above-mentioned antibodies of the present invention,
  • the method is selected from the following:
  • the ligand of IL-12/IL-23 p40 is IL-12R ⁇ 1 or IL-23R.
  • the in vitro method is for non-therapeutic or diagnostic purposes.
  • Another aspect of the present invention relates to any one of the above-mentioned antibodies or antigen-binding fragments, antibody conjugates, multispecific antibodies, fusion proteins or pharmaceutical compositions of the present invention in preparing prevention and/or treatment and/or auxiliary Application in drugs for the treatment and/or diagnosis of autoimmune diseases (such as plaque psoriasis, systemic lupus erythematosus) or ulcerative colitis (such as refractory or relapsed), or for prevention and/ Or treatment and/or adjuvant treatment and/or diagnosis of autoimmune diseases (such as plaque psoriasis, systemic lupus erythematosus) or ulcerative colitis (such as refractory or relapsed) application.
  • autoimmune diseases such as plaque psoriasis, systemic lupus erythematosus
  • ulcerative colitis such as refractory or relapsed
  • the drug is in a form suitable for administration by subcutaneous injection, intradermal injection, intravenous injection, intramuscular injection or intralesional injection.
  • Another aspect of the present invention relates to the prevention and/or treatment and/or adjuvant treatment and/or diagnosis of autoimmune diseases (such as plaque psoriasis, systemic lupus erythematosus) or ulcerative colitis (such as refractory (Or relapse) method, comprising administering to a subject in need the antibody or antigen-binding fragment thereof, antibody conjugate, multispecific antibody, fusion protein or pharmaceutical composition of any one of the above in the present invention.
  • autoimmune diseases such as plaque psoriasis, systemic lupus erythematosus
  • ulcerative colitis such as refractory (Or relapse)
  • the present invention also provides a method for treating a patient suffering from ulcerative colitis, the method comprising: (i) measuring the human IL-12/IL-23 p40 level in a sample of the patient, wherein the patient Is human IL-12/IL-23 p40 positive, and (ii) administering a therapeutically effective amount of anti-human IL-12/IL-23 p40 antibody or an antigen-binding portion thereof to the subject.
  • ulcerative colitis of the present invention can be refractory and relapsed.
  • ulcerative colitis is recurrent; in some patients, ulcerative colitis is refractory.
  • the patient has previously received conventional treatment or has insufficiently responded, lost response, or is intolerant to biological agents.
  • the said has received conventional treatment or has insufficient response, loss of response or intolerance to the biological agent, resulting in failure to complete remission or failure to partial remission.
  • H8L15H1L1 is an anti-human IL-12/IL-23 p40 monoclonal antibody, and its sequence and structure can be found in the patent document (CN201910706137.1).
  • HCDR1 contains the sequence GYTFTSYW (SEQ ID NO: 3)
  • HCDR2 contains the sequence MSPVDSDI (SEQ ID NO: 4)
  • HCDR3 contains the sequence ARRRPGQGYFDF (SEQ ID NO: 5)
  • LCDR1 contains the sequence QSVGTW ( SEQ ID NO: 6)
  • LCDR2 includes the sequence AAS (SEQ ID NO: 7)
  • LCDR3 includes the sequence QQYNIYPYT (SEQ ID NO: 8).
  • the term "antigen binding region” means a protein or part of a protein that specifically binds to a specified antigen.
  • the antigen binding region usually includes one or more "complementarity-determining regions” (CDR).
  • CDR complementarity-determining regions
  • Certain antigen binding regions also include one or more "framework regions” (FR).
  • CDRs are amino acid sequences that contribute to antigen binding specificity and affinity.
  • antibody refers to intact immunoglobulins of any isotype or antigen-binding fragments thereof that can compete with intact antibodies for specific binding to the target antigen, and includes, for example, chimeric antibodies, Humanized antibodies, fully humanized antibodies and bispecific antibodies or antigen-binding fragments thereof.
  • antibodies are types of antigen binding proteins. Intact antibodies usually contain at least two full-length heavy chains and two full-length light chains, but in some cases, may include fewer chains, such as antibodies naturally occurring in camelids that may contain only heavy chains.
  • the antibody or antigen-binding fragment thereof may be derived from a single source only, or may be "chimeric", that is, different parts of the antibody may be derived from two different sources as described further below.
  • Antibodies or antigen-binding fragments thereof can be produced in hybridomas by recombinant DNA technology, or by enzymatic or chemical cleavage of whole antibodies.
  • the term “antibody” or “antigen-binding fragment” (or “fragment” for short) of an “immunoglobulin chain (heavy or light chain)” includes the absence of at least some of the full-length antibody chain The amino acids in but the part of the antibody that can specifically bind to the antigen (this part is obtained or synthesized anyway). Such fragments are biologically active because they specifically bind to the target antigen and can compete with other antibodies or antigen-binding fragments thereof for specific binding to a given epitope. In one aspect, such fragments will retain at least one CDR present in the full-length light or heavy chain of the antibody, and in some embodiments will comprise a single heavy chain and/or light chain or a portion thereof.
  • Immunologically functional immunoglobulin fragments include, but are not limited to Fab, Fab', F(ab') 2 , Fv, Fd, dAb, Fab/c, complementarity determining region (CDR) fragments, single-chain antibodies (for example, scFv) , Bivalent antibodies and domain antibodies, and can be derived from any mammalian source, including but not limited to human, mouse, rat, camelid or rabbit.
  • the functional portion of the antibody disclosed herein can be covalently bound to a second protein or small molecule to generate a therapeutic agent directed to a specific target in the body, thereby having bifunctional therapeutic properties or having Prolonged serum half-life, such as fusion proteins.
  • antibody full-length chain As used in the present invention, the terms “antibody full-length chain”, “full-length antibody”, “intact antibody” and “whole antibody” are used interchangeably herein to refer to such
  • the antibody has a structure substantially similar to the structure of a natural antibody or a heavy chain with an Fc region as defined herein.
  • the term "light chain” includes full-length light chains and their fragments with sufficient variable region sequences to confer binding specificity. Domain comprises a full length light chain V domain C L L variable regions and constant regions. The variable domain of the light chain is at the amino terminal end of the polypeptide.
  • the light chain includes kappa chain and lambda chain.
  • the term "heavy chain” includes the full-length heavy chain and its fragments with sufficient variable region sequence to confer binding specificity.
  • Full length heavy chain includes a variable region domain and V H domain C H1, C H2 C H3 3, and two constant region.
  • V H domain is at the amino terminus of a polypeptide, and the C H domain at the carboxy terminus, C H3 closest to the carboxy terminus of a polypeptide.
  • the heavy chain can be of any isotype, including IgG (including IgG1, IgG2, IgG3, and IgG4 subtypes), IgA (including IgAl and IgA2 subtypes), IgM, and IgE.
  • Fab fragment consists of a light chain and CH1 and the variable region of a heavy chain.
  • the heavy chain of the Fab molecule cannot form a disulfide bond with another heavy chain molecule.
  • Fc region contains a fragment of the heavy chain C H2 and C H1 domains of the two antibodies comprises.
  • the two heavy chain fragments are held together by two or more disulfide bonds and by the hydrophobic interaction of the CH3 domain.
  • Fab 'fragment contains one light chain and one heavy chain portion (which contains the region between the V H and C H1 domain and also the C H1 domain and the C H2 domain ), so that an interchain disulfide bond can be formed between the two heavy chains of two Fab' fragments to form F(ab') 2 molecules.
  • F (ab ') 2 fragment contains two light chains and two heavy chains containing a portion of the constant region between the C H2 and C H1 domain, so the two heavy Interchain disulfide bonds are formed between the chains.
  • the F(ab') 2 fragment thus consists of two Fab' fragments held together by the disulfide bond between the two heavy chains.
  • Fv region includes variable regions derived from heavy and light chains, but lacks constant regions.
  • Fd fragment means an antibody fragment composed of VH and CH1 domains (Ward et al., Nature 341:544-546 (1989)).
  • dAb dAb fragment (Ward et al., Nature 341: 544-546 (1989) ) by the V H domain.
  • Fab'-SH is the designation for Fab' herein, in which one or more cysteine residues of the constant domain carry a free thiol group.
  • Fab/c fragment is an intermediate product of antibody cleavage formed by pepsin digestion of immunoglobulins. It has the advantages of both Fab and Fc regions, that is, it has strong diffusion ability and slow metabolism in vivo. It can maintain high affinity (Liu Jianjun, "Journal of Cellular and Molecular Immunology", 1989(4): 29-29).
  • single chain antibody is an Fv molecule in which the variable regions of the heavy chain and the light chain are connected by a flexible linker to form a single polypeptide chain (which forms the antigen binding region) (see, for example, Bird et al. Human, Science 242: 423-426 (1988) and Huston et al., Proc. Natl. Acad. Sci. USA. 90: 5879-5883 (1988)).
  • Single-chain antibodies are described in detail in International Patent Application Publication No. WO88/01649 and U.S. Patent 4,946,778 and U.S. Patent 5,260,203 (the disclosures of the International Patent Application Publication No. and U.S. Patent No. are incorporated by reference).
  • domain antibody is an immunologically functional immunoglobulin fragment containing only the variable region of the heavy chain or the variable region of the light chain.
  • two or more VH regions are covalently linked by a peptide linker to generate multivalent domain antibodies (especially bivalent domain antibodies).
  • the two VH regions of a bivalent domain antibody can target the same or different antigens.
  • bivalent antigen binding protein or “bivalent antibody” includes two antigen binding sites. In some cases, the two binding sites have the same antigen specificity. Bivalent antibodies can be bispecific.
  • multispecific antigen binding protein or “multispecific antibody” is an antigen binding protein or antibody that targets more than one antigen or epitope.
  • bispecific As used in the present invention, the terms "bispecific,” “dual specific,” or “bifunctional” antigen binding protein or antibody are hybrid antigen binding proteins or antibodies each having two different antigen binding sites.
  • a bispecific antibody is a multispecific antigen binding protein or multispecific antibody, and can be produced by a variety of methods, including, but not limited to, the fusion of hybridomas or the linking of Fab' fragments. See, for example, Songsivilai and Lachmann, 1990, Clin. Exp. Immunol. 79: 315-321; Kostelny et al., 1992, J. Immunol. 148: 1547-1553.
  • the two binding sites of the bispecific antigen binding protein or antibody will bind to two different epitopes that are present on the same or different protein targets.
  • the terms "monoclonal antibody” and “monoclonal antibody” refer to an antibody or a fragment of an antibody from a group of highly homologous antibody molecules, that is, in addition to natural mutations that may occur spontaneously , A group of identical antibody molecules.
  • the monoclonal antibody has high specificity for a single epitope on the antigen.
  • Polyclonal antibodies are relative to monoclonal antibodies, which usually contain at least two or more different antibodies, and these different antibodies usually recognize different epitopes on the antigen.
  • Monoclonal antibodies can usually be obtained using hybridoma technology first reported by Kohler et al. (Nature 256:495, 1975), but can also be obtained using recombinant DNA technology (see U.S. Patent 4,816,567, for example).
  • humanized antibody means that all or part of the CDR region of a human immunoglobulin (acceptor antibody) is replaced by a CDR region of a non-human antibody (donor antibody)
  • the obtained antibody or antibody fragment wherein the donor antibody may be a non-human (e.g., mouse, rat or rabbit) antibody with the expected specificity, affinity or reactivity.
  • some amino acid residues in the framework region (FR) of the acceptor antibody can also be replaced by corresponding non-human antibody amino acid residues, or by other antibody amino acid residues, to further improve or optimize antibody performance.
  • epitope refers to a site on an antigen that is specifically bound by an immunoglobulin or antibody.
  • Epitope is also called “antigenic determinant” in the art.
  • Epitopes or antigenic determinants usually consist of chemically active surface groups of molecules such as amino acids or carbohydrates or sugar side chains and usually have specific three-dimensional structural characteristics and specific charge characteristics.
  • an epitope usually includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 consecutive or non-contiguous amino acids in a unique spatial conformation, which can be "linear ⁇ " or “conformational”. See, for example, Epitope Mapping Protocols in Methods in Molecular Biology, Volume 66, G.E. Morris, Ed.
  • polypeptide or "protein” is used herein to refer to a polymer of amino acid residues.
  • the term is also used for amino acid polymers in which one or more amino acid residues are analogs or mimetics of the corresponding naturally occurring amino acid, as well as for naturally occurring amino acid polymers.
  • the term may also include amino acid polymers that have been modified or phosphorylated, for example, by adding carbohydrate residues to form glycoproteins.
  • Polypeptides and proteins can be produced by naturally occurring cells and non-recombinant cells; or they are produced by genetic engineering or recombinant cells, and contain molecules with the amino acid sequence of a natural protein, or deletions, additions, and deletions of one or more amino acids of the natural sequence. / Or substituted molecules.
  • polypeptide and protein include antibodies, such as anti-human p40 antibodies (also known as p40 antibodies), p40 binding proteins, those having one or more amino acid deletions, additions, and/or substitutions of antigen binding proteins.
  • Antibody or sequence include antibodies, such as anti-human p40 antibodies (also known as p40 antibodies), p40 binding proteins, those having one or more amino acid deletions, additions, and/or substitutions of antigen binding proteins.
  • polypeptide fragment refers to a polypeptide having amino-terminal deletions, carboxy-terminal deletions, and/or internal deletions compared to full-length proteins. Such fragments may also contain modified amino acids compared to full-length proteins. In certain embodiments, the length of the fragment is about 5 to 500 amino acids. For example, the length of the fragment can be at least 5, 6, 8, 10, 14, 20, 50, 70, 100, 110, 150, 200, 250, 300, 350, 400, or 450 amino acids in length.
  • Useful polypeptide fragments include immunologically functional fragments of antibodies, including binding domains. In the case of a human p40 antibody, useful fragments include but are not limited to CDR regions, variable domains of heavy or light chains, parts of antibody chains, or variable domains that just include two CDRs thereof.
  • a “derivative" of a polypeptide is a polypeptide that is chemically modified by conjugation of another chemical moiety (e.g., antigen binding protein or antibody) in a manner different from insertion, deletion or substitution variants, e.g., PEG-conjugated Peptides.
  • another chemical moiety e.g., antigen binding protein or antibody
  • the terms “isolated” or “isolated” refer to those obtained from the natural state by artificial means. If a certain "isolated” substance or component appears in nature, it may be that the natural environment in which it is located has changed, or the substance has been isolated from the natural environment, or both. For example, a certain unisolated polynucleotide or polypeptide naturally exists in a living animal, and the same polynucleotide or polypeptide with high purity isolated from this natural state is called isolation. of.
  • isolation a certain unisolated polynucleotide or polypeptide naturally exists in a living animal, and the same polynucleotide or polypeptide with high purity isolated from this natural state is called isolation. of.
  • isolation polynucleotide or polypeptide with high purity isolated from this natural state is called isolation. of.
  • isolated does not exclude the mixing of artificial or synthetic materials, nor does it exclude the presence of other impure materials that do not affect the activity of the material.
  • the term "vector” refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted.
  • the vector can express the protein encoded by the inserted polynucleotide, the vector is called an expression vector.
  • the vector can be introduced into the host cell through transformation, transduction or transfection, so that the genetic material elements it carries can be expressed in the host cell.
  • Vectors are well known to those skilled in the art, including but not limited to: plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or P1 derived artificial chromosomes (PAC) ; Phages such as lambda phage or M13 phage and animal viruses.
  • artificial chromosomes such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or P1 derived artificial chromosomes (PAC)
  • Phages such as lambda phage or M13 phage and animal viruses.
  • Animal viruses that can be used as vectors include, but are not limited to, retrovirus (including lentivirus), adenovirus, adeno-associated virus, herpes virus (such as herpes simplex virus), poxvirus, baculovirus, papilloma virus, and papillary Polyoma vacuole virus (such as SV40).
  • retrovirus including lentivirus
  • adenovirus adeno-associated virus
  • herpes virus such as herpes simplex virus
  • poxvirus such as herpes simplex virus
  • baculovirus baculovirus
  • papilloma virus papilloma virus
  • papillary Polyoma vacuole virus such as SV40
  • a vector can contain a variety of elements that control expression, including but not limited to promoter sequences, transcription initiation sequences, enhancer sequences, selection elements and reporter genes.
  • the vector may also contain an origin of replication site.
  • the term "host cell” refers to a cell that can be used to introduce a vector, including but not limited to prokaryotic cells such as Escherichia coli or Bacillus subtilis, and fungal cells such as yeast cells or Aspergillus , Such as insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK293 cells or human cells.
  • prokaryotic cells such as Escherichia coli or Bacillus subtilis
  • fungal cells such as yeast cells or Aspergillus
  • insect cells such as S2 Drosophila cells or Sf9
  • animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK293 cells or human cells.
  • the term "specific binding” refers to a non-random binding reaction between two molecules, such as the reaction between an antibody and the antigen it targets.
  • an antibody that specifically binds to a certain antigen means that the antibody has a concentration of less than about 10 -5 M, such as less than about 10 -6 M, 10 -7 M, An affinity (K D ) of 10 -8 M, 10 -9 M, or 10 -10 M or less binds the antigen.
  • K D refers to the dissociation equilibrium constant of a specific antibody-antigen interaction, which is used to describe the binding affinity between the antibody and the antigen.
  • K D is the dissociation equilibrium constant. In antibody drug research, it is a parameter that characterizes the affinity between the tested antibody and the target antigen molecule.
  • the binding rate constant the rate at which the antigen-antibody complex is formed, the smaller kon indicates the faster the antibody binds to the antigen;
  • kdis, the dissociation rate constant the rate at which the antibody dissociates from the antigen-antibody complex, the smaller the kdis That is, the slower the rate at which the antibody detaches from the antigen, the stronger the binding of the antibody to the antigen.
  • the antibody has a dissociation equilibrium constant (K D ) less than about 10 -5 M, for example, less than about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, or 10 -10 M or less Bound antigen (e.g., L1 protein), for example, as determined in a Fortebio molecular interaction instrument using biofilm interference technology (BLI).
  • K D dissociation equilibrium constant
  • EC50 refers to the effective concentration, 50% of the maximum response of the antibody.
  • the terms “monoclonal antibody” and “monoclonal antibody” have the same meaning and can be used interchangeably; the terms “polyclonal antibody” and “polyclonal antibody” have the same meaning and can be used interchangeably.
  • amino acids are usually represented by one-letter and three-letter abbreviations well known in the art.
  • alanine can be represented by A or Ala.
  • percent sequence identity As used herein, the terms “percent sequence identity” and “percent sequence homology” are used interchangeably.
  • the terms “similarity” or “sequence similarity” and “identity” refer to the relationship between the sequences of two or more protein or polypeptide molecules, as determined by alignment and comparison of sequences .
  • Perfect identity means the percentage of identical residues between amino acids in the molecules being compared, and can be calculated based on the size of the smallest molecule to be compared. In order to perform these calculations, a specific mathematical model or computer program (ie, “algorithm”) must be used to resolve the gaps in the alignment (if any).
  • algorithm ie, “algorithm”
  • the optimal alignment is at least 70% in total. 75% or 80% sequence identity, at least 90% or 95% sequence identity, and at least 97%, 98%, or 99% sequence identity.
  • residues that are not identical differ by conservative amino acid substitutions.
  • a "conservative amino acid substitution” is a substitution in which an amino acid residue is replaced by another amino acid residue having a side chain R group that possesses similar chemical properties (eg, charge or hydrophobicity). Generally, conservative amino acid substitutions will not substantially change the functional properties of the protein.
  • the percent sequence identity can be adjusted upward to correct for the conservative nature of the substitutions.
  • the method for making this adjustment is well known to those skilled in the art. See, for example, Pearson, Methods Mol. Biol. 243: 307-31 (1994).
  • amino acid groups having side chains with similar chemical properties include 1) aliphatic hydroxyl side chains: glycine, alanine, valine, leucine, and isoleucine; 2) aliphatic hydroxyl side chains: serine And threonine; 3) amide-containing side chain: asparagine and glutamine; 4) aromatic side chain: phenylalanine, tyrosine and tryptophan; 5) basic side chain: lysine , Arginine and histidine; 6) acidic side chains: aspartic acid and glutamic acid; and 7) sulfur-containing side chains: cysteine and methionine.
  • the conservative amino acid substitution group is valine-leucine-isoleucine-alanine-glycine, phenylalanine-tyrosine, lysine-arginine, threonine-serine, glutamine Acid-aspartic acid and asparagine-glutamine.
  • a conservative substitution is any change that has a positive value in the PAM250 log-likelihood matrix (PAM2501og-likelihood matrix) disclosed in Gonnet et al., Science 256:1443-45 (1992) (incorporated herein by reference) .
  • a “moderately conservative” substitution is any change that has a non-negative value in the PAM250 log-likelihood matrix.
  • Sequence analysis software is usually used to measure the sequence identity of polypeptides. Protein analysis software uses measures of similarity assigned to different substitutions, deletions, and other modifications (including conservative amino acid substitutions) to match sequences. For example, GCG includes programs such as "Gap” and "Bestfit” which can be used to determine closely related polypeptides (such as homologous polypeptides from different biological species) or wild-type proteins (using default parameters specified by the program). Sequence homology or sequence identity between its mutant protein. See, for example, GCG Version 6.1 (University of Wisconsin, WI). You can also use the default or recommended parameters to compare peptide sequences using FASTA. See GCG Version 6.10 FASTA (e.g.
  • FASTA2 and FASTA3 provides alignment and percent sequence identity of the best overlapping region between the challenge sequence and the search sequence ( Pearson, Methods Enzymol. 183: 63-98 (1990); Pearson, Methods Mol. Biol. 132: 185-219 (2000)).
  • another preferred algorithm is the computer program BLAST, in particular, blastp or blastn (using the default parameters provided by the program). See, for example, Altschul et al., Mol. Biol. 215: 403-410 (1990); Altschul et al., Nucleic Acids Res. 25: 3389-402 (1997).
  • treatment generally refers to an operation to obtain a desired pharmacological and/or physiological effect.
  • the effect may be prophylactic in terms of completely or partially preventing the disease or its symptoms; and/or may be therapeutic in terms of partially or completely stabilizing or curing the disease and/or side effects due to the disease.
  • Treatment covers any treatment of a patient's disease, including: (a) preventing diseases or symptoms in patients who are susceptible to diseases or symptoms but have not yet been diagnosed with the disease; (b) suppressing disease symptoms, That is to prevent its development; or (c) alleviate the symptoms of the disease, that is, cause the disease or symptoms to degenerate.
  • systemic therapy refers to treatment in which a drug substance is transported through the bloodstream to reach and affect cells throughout the body.
  • systemic chemotherapy refers to systemic chemotherapy that does not include chemotherapy for locally advanced disease as a part of multimodal treatment.
  • chemotherapy for locally advanced disease includes induction chemotherapy, concurrent chemotherapy with radiotherapy, and adjuvant Chemotherapy.
  • the term "subject” refers to mammals such as rodents, felines, canines, and primates.
  • the subject of the invention is a human.
  • administering means using any of a variety of methods and delivery systems known to those skilled in the art to physically introduce a composition containing a therapeutic agent to a subject.
  • the route of administration of autoimmune disease-related factor inhibitors includes intravenous, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral administration routes, such as by injection or Infusion.
  • parenteral administration refers to modes of administration other than enteral and local administration that are usually performed by injection, and include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, and intralymphatic , Intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspine, epidural and intrasternal injections and infusions , And electroporation in vivo.
  • the autoimmune disease-related factor inhibitor (for example, anti-human IL-12/IL-23 p40 antibody) is administered by non-parenteral routes, and in certain embodiments, orally.
  • non-parenteral routes include topical, epidermal or mucosal routes of administration, for example, intranasal, vaginal, rectal, sublingual, or topical. Administration can also be performed, for example, once, multiple times, and/or over one or more extended periods of time.
  • Subject includes any human or non-human animal.
  • non-human animal includes, but is not limited to, vertebrates such as non-human primates, sheep, dogs, and rodents such as mice, rats, and guinea pigs.
  • the subject is a human.
  • the terms “subject” and “patient” are used interchangeably herein.
  • the term “about”, “approximately” or “substantially comprising” means a value or composition within an acceptable error range of a particular value or composition determined by a person of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined. Composition, that is, the limits of the measurement system. For example, “about”, “approximately” or “substantially comprising” can mean within 1 or more than 1 standard deviation according to practice in the art. Alternatively, “about” or “substantially comprising” may refer to a range that differs from the parameter or value modified by it by at most 10% or 20% (ie, ⁇ 10% or ⁇ 20%). For example, about 3 mg can include any number between 2.7 mg and 3.3 mg (for 10%) or 2.4 mg and 3.6 mg (for 20%).
  • the following content does not limit the administration mode of the drug of the application.
  • the medicament of the present application can be formulated into a pharmaceutical composition suitable for single or multiple administration.
  • the drugs of this application are administered by various suitable routes, including but not limited to oral or parenteral (by intravenous, intramuscular, topical or subcutaneous routes).
  • the medicament of the application is administered orally or by injection, such as intravenous injection or intraperitoneal injection.
  • Suitable dosage forms of the medicine of this application include, but are not limited to, tablets, troches, pills, capsules (such as hard capsules, soft capsules, enteric capsules, microcapsules), elixirs, granules, syrups, injections (Intramuscular, intravenous, intraperitoneal), granules, emulsions, suspensions, solutions, dispersions, and dosage forms of sustained-release preparations for oral or parenteral administration.
  • the medicine of this application contains pharmaceutically acceptable carriers and/or excipients.
  • the humanized antibody against human IL-12/IL-23 p40 protein domain of the present invention can specifically bind to IL-12/IL-23 p40 protein domain, and can effectively block IL-12/IL-23 p40 protein
  • the binding of the domain to the cell surface receptor IL-12R ⁇ 1 and IL-23R inhibits the activation of the downstream signaling pathway of the human IL-12/IL-23 p40 protein domain, and inhibits the secretion of IL-17A induced by IL-23.
  • the binding activity of the antibody of the present invention to human p40 is significantly better than the control antibodies Ustekinumab and Ab123FR1.
  • Figure 1 The detection results of the binding activity of H5L9 and Ab123FR1 to human IL-12/IL-23 p40 protein domain.
  • Figure 2 The detection results of the binding activity of H5L10 and Ab123FR1 to human IL-12/IL-23 p40 protein domain.
  • Figure 3 The detection results of the binding activity of H5L11, H5L12, H5L14 and Ab123FR1 to human IL-12/IL-23 p40 protein domain.
  • Figure 4 Test results of binding activity of H8L15 and Ab123FR1 to human IL-12/IL-23 p40 protein domain.
  • Figure 5 The result of the detection of the affinity constant between H5L9 and human IL-12/IL-23 p40 protein domain.
  • concentration of antibody added to each pair of curves from top to bottom in the figure is 5nM, 2.5nM, 1.25nM, 0.75nM, 0.31nM, respectively.
  • Figure 6 The result of the detection of the affinity constant between H5L10 and human IL-12/IL-23 p40 protein domain.
  • concentration of antibody added to each pair of curves from top to bottom in the figure is 5nM, 2.5nM, 1.25nM, 0.75nM, 0.31nM, respectively.
  • Figure 7 The result of the detection of the affinity constant between H5L11 and human IL-12/IL-23 p40 protein domain.
  • concentration of antibody added to each pair of curves from top to bottom in the figure is 5nM, 2.5nM, 1.25nM, 0.75nM, 0.31nM, respectively.
  • Figure 8 The result of the detection of the affinity constant between H5L12 and human IL-12/IL-23 p40 protein domain.
  • the concentration of antibody added to each pair of curves from top to bottom in the figure is 5nM, 2.5nM, 1.25nM, 0.75nM, 0.31nM, respectively.
  • Figure 9 The result of the detection of the affinity constant between H5L14 and human IL-12/IL-23 p40 protein domain.
  • the concentration of antibody added to each pair of curves from top to bottom in the figure is 5nM, 2.5nM, 1.25nM, 0.75nM, 0.31nM, respectively.
  • Figure 10 The result of the detection of the affinity constant between Ab123FR1 and human IL-12/IL-23 p40 protein domain.
  • concentration of antibody added to each pair of curves from top to bottom in the figure is 5nM, 2.5nM, 1.25nM, 0.75nM, 0.31nM, respectively.
  • Figure 11 The result of the detection of the affinity constant between H8L15 and human IL-12/IL-23 p40 protein domain.
  • the concentration of antibody added to each pair of curves from top to bottom in the figure is 5nM, 2.5nM, 1.25nM, 0.75nM, 0.31nM, respectively.
  • Figure 12 The result of the detection of the affinity constant between Ustekinumab and human IL-12/IL-23 p40 protein domain.
  • concentration of antibody added to each pair of curves from top to bottom in the figure is 5nM, 2.5nM, 1.25nM, 0.75nM, 0.31nM, respectively.
  • H5L9, H5L10, H5L11, H5L12, H5L14 and Ustekinumab antibodies competitively block the binding of human IL-12 to 293T-IL-12R ⁇ 1 & IL-23R cells (FACS).
  • H5L9, H5L10, H5L11, H5L12, H5L14 and Ustekinumab antibodies competitively block the binding of human IL-23 to 293T-IL-12R ⁇ 1 & IL-23R cells (FACS).
  • Figure 17 shows the statistical results of the pathological scores of ulcerative colitis in each experimental group. H8L15 significantly relieved the pathological changes and clinical symptoms of ulcerative colitis model mice.
  • Figure 19 Demonstration of histopathological observation of the skin tissue of mice with colitis induced by DSS combined with recombinant human IL-23 by H8L15.
  • mice used were purchased from Guangdong Medical Experimental Animal Center.
  • the IL-12 Human IL12 (His Tag) used was purchased from Yiqiao Shenzhou (product number: CT-050-H08H-20, batch number: LC11MC2805).
  • the anti-IL-12/IL-23 p40 antibody Ab123FR1 used is used as a control antibody.
  • Its preparation method refers to a Chinese authorized patent, publication number: CN103275222B, produced by Zhongshan Kangfang Biomedicine Co., Ltd., The sequence is shown in the 20th to 468th position of SEQ ID NO: 3 and the 20th to 233rd position of SEQ ID NO: 4 in CN103275222B.
  • the used anti-p40 antibody Ustekinumab (trade name Stelara), a marketed drug with the same target, was used as a control antibody and was purchased from Johnson & Johnson.
  • the 293T-IL-12R ⁇ 1&IL-23R cell line used was constructed by Zhongshan Kangfang Biomedicine Co., Ltd.
  • the 293T-IL-12R ⁇ 1&IL-23R cell line is prepared by virus infection of 293T cells.
  • the virus preparation uses 3rd Generation Lentiviral Systems, see, for example, A Third Generation Lentivirus Vector with a Conditional Packaging System.Dull T, Zufferey R, Kelly M , Mandel RJ, Nguyen M, Trono D, and Naldini LJ Virol. 1998.72(11): 8463-8471.
  • the lentiviral expression vector used is pLenti-IL-12R ⁇ 1-BSD (IL-12R ⁇ 1, GenBank accession number: 3549; vector pLenti-BSD, purchased from invitrogen, Cat#K497000) and pCDH-IL-23R-puro (where IL-23R, GenBank accession number: 149233; vector pCDH-CMV-MCS-EF1-Puro, purchased from Youbao Biology, product number: VT1480).
  • the isotype control antibody is human anti-Hen Egg Lysozyme IgG (anti-HEL, namely human IgG, hIgG1 for short), and its sequence comes from Affinity maturation increases the stability and plasticity of the Fv domain published by Acierno et al. of anti-protein antibodies (Acierno et al. J Mol Biol. 2007; 374(1): 130-46., wherein the amino acid sequence of the heavy chain is shown in SEQ ID NO: 21, and the amino acid sequence of the light chain is SEQ ID NO : 22), the isotype control antibody designed for this study was prepared in the laboratory of Zhongshan Kangfang Biomedical Co., Ltd.
  • the hIL-23 recombinant protein (IL-23, GeneBank, accession number: 51561) was prepared in the laboratory of Zhongshan Kangfang Biomedical Co., Ltd.
  • Example 1 Design, expression and purification of heavy chain and light chain sequences of anti-human p40 antibody H8L15
  • the present inventors In order to prepare the anti-human IL-12/IL-23 p40 antibody H8L15, the present inventors based on the IL-12/IL-23 p40 protein domain structure, through the three-dimensional structure simulation technology of antigen-antibody binding based on structural biology, The interaction between the CDR region and the antigen is calculated by quantum simulation calculation to determine the amino acid sequence of the CDR region where the antibody binds to the antigen; at the same time, the antibody framework is optimized based on the three-dimensional structure of the CDR region, and finally obtained A kind of antibodies H5L9, H5L10, H5L11, H5L12, H5L14, H8L15 that specifically bind to human IL-12/IL-23 p40.
  • amino acid sequence of the antibody heavy chain/light chain variable region and its coding DNA sequence are as follows:
  • H5L9 The amino acid sequence of the variable region of the heavy chain is shown in SEQ ID NO: 1, and its coding DNA sequence is shown in SEQ ID NO: 2;
  • H5L9 The amino acid sequence of the light chain variable region is shown in SEQ ID NO: 6, and its coding DNA sequence is shown in SEQ ID NO: 7;
  • H5L10 The amino acid sequence of the variable region of the heavy chain is shown in SEQ ID NO: 1, and its coding DNA sequence is shown in SEQ ID NO: 2;
  • H5L10 The amino acid sequence of the light chain variable region is shown in SEQ ID NO: 11, and its coding DNA sequence is shown in SEQ ID NO: 12;
  • H5L11 The amino acid sequence of the variable region of the heavy chain is shown in SEQ ID NO: 1, and its coding DNA sequence is shown in SEQ ID NO: 2;
  • H5L11 The amino acid sequence of the light chain variable region is shown in SEQ ID NO: 13, and its coding DNA sequence is shown in SEQ ID NO: 14;
  • H5L12 The amino acid sequence of the variable region of the heavy chain is shown in SEQ ID NO: 1, and the coding DNA sequence is shown in SEQ ID NO: 2;
  • H5L12 The amino acid sequence of the light chain variable region is shown in SEQ ID NO: 15, and its coding DNA sequence is shown in SEQ ID NO: 16;
  • H5L14 The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 1, and its coding DNA sequence is shown in SEQ ID NO: 2;
  • H5L14 The amino acid sequence of the light chain variable region is shown in SEQ ID NO: 17, and its coding DNA sequence is shown in SEQ ID NO: 18;
  • H8L15 The amino acid sequence of the variable region of the heavy chain is shown in SEQ ID NO: 24, and its coding DNA sequence is shown in SEQ ID NO: 37;
  • H8L15 The amino acid sequence of the light chain variable region is shown in SEQ ID NO: 25, and its coding DNA sequence is shown in SEQ ID NO: 38
  • H8L15 heavy chain variable region coding nucleotide sequence (as shown in SEQ ID NO: 37; constant region is Ig gamma-1 chain C region, ACCESSION: P01857) and light chain variable region coding
  • the nucleotide sequence (as shown in SEQ ID NO: 38; the constant region is Ig kappa chain C region, ACCESSION: P01834) was cloned into the pUC57simple vector (provided by GenScript) to obtain the full length of the heavy chain containing H8L15.
  • the nucleotide pUC57simple-H8L15H and the pUC57simple-H8L15L plasmid containing the full-length nucleotide of the light chain of H8L15.
  • the plasmids pUC57simple-H8L15H and pUC57simple-H8L15L were digested (HindIII&EcoRI), and the heavy chain/light chain nucleotide sequences recovered by electrophoresis were subcloned into pcDNA3.1 vector, and the recombinant plasmids were extracted and co-transfected into 293F cells. After the transfected 293F cells were cultured for 7 days, the culture medium was centrifuged at a high speed, and the supernatant obtained was concentrated and loaded onto the HiTrap MabSelect SuRe column. The protein was eluted in one step with the eluent to recover the target sample. Antibody samples are stored in PBS solution.
  • the preparation of other antibodies is the same.
  • the antibodies H5L9, H5L10, H5L11, H5L12, H5L14, and H8L15 prepared in this example were used in Examples 2 to 4 below.
  • Example 2 ELISA method to detect the binding activity of antibodies H5L9, H5L10, H5L11, H5L12, H5L14, H8L15, Ab123FR1 and Ustekinumab and antigen human IL-12/IL-23 p40
  • HRP-labeled goat anti-human IgG (H+L) (purchased from Jackson ImmunoResearch Inc., catalog number: 109-035-088) diluted with a ratio of 1:5000 and incubate at 37°C for 30 minutes . After the incubation was completed, the plate was washed and patted dry with PBST, TMB (Neogen, 308177) was added for 5 minutes to develop color in the dark, and stop solution was added to terminate the color reaction. Immediately put the microplate reader into the microplate reader, select the 450nm light wavelength to read the OD value of each well of the microplate. Use SoftMax Pro 6.2.1 software to analyze and process the data.
  • H5L9 binding to human p40-His is the EC 50 0.079nM
  • Ab123FR1 binding to human p40-His is the EC 50 0.063nM.
  • the binding efficiency of H5L9 and Ab123FR1 is comparable.
  • H5L10 binding to human p40-His as the EC 2 50 0.057nM
  • Ab123FR1 binding to human p40-His is the EC 50 0.051nM.
  • the binding efficiency of H5L10 and Ab123FR1 is comparable.
  • the EC50 of H5L11, H5L12, H5L14 and Ab123FR1 binding to human p40-His were 0.082 nM, 0.082 nM, 0.107 nM and 1.181 nM, respectively.
  • the binding efficiency of H5L11, H5L12, and H5L14 is significantly better than that of Ab123FR1.
  • the EC50 of H8L15, Ab123FR1, Ustekinumab and human p40-His were 0.059nM, 0.074nM and 0.077nM, respectively.
  • the binding efficiency of Ab123FR1 and Ustekinumab is equivalent, while the binding efficiency of H8L15 is significantly better than that of Ab123FR1 and Ustekinumab.
  • H5L9, H5L10, H5L11, H5L12, H5L14, H8L15, Ab123FR1 and Ustekinumab sample dilution buffer is PBS, 0.02% Tween-20, 0.1% BSA, pH 7.4.
  • the p40-His was fixed on HIS1K (manufacturer: Fortebio, article number: 18-5120) sensor at a concentration of 1 ⁇ g/mL for 40 seconds.
  • the sensor is equilibrated in the buffer for 60s, and the p40-His immobilized on the sensor binds to the antibody at a concentration of 5-0.31nM (two-fold dilution) for 120s.
  • the protein dissociates in the buffer for 300s.
  • the detection temperature is 37°C
  • the detection frequency is 0.3 Hz
  • the sample plate vibration rate is 500 rpm.
  • the data was analyzed by a 1:1 model to get the affinity constant.
  • the affinity constant of human p40-His is 9.05E-11M
  • the affinity constant of H5L14 and human p40-His is 6.20E-11M
  • the affinity constant of Ab123FR1 and human p40-His is 7.40E-11M
  • the affinity constant of H8L15 and human p40-His is 6.09E-11M
  • the affinity constant between Ustekinumab and human p40-His is 8.64E-11M.
  • the affinity is H8L15, H5L14, Ab123FR1, Ustekinumab, H5L12, H5L10, H5L11, H5L9
  • H8L15 and H5L14 have stronger affinity with human p40-His than Ab123FR1 and Ustekinumab.
  • Example 4 Flow cytometry detection of anti-human IL-12/IL-23 p40 antibody competitively blocking the binding of human IL-12, IL-23 and 293T-IL-12R ⁇ 4&IL-23R cells
  • Alexa 488 anti-His Tag Antibody is diluted 1:400 (Biolegend, catalog number: 652509), add 100 ⁇ L to each tube, mix well, and incubate for 40min on ice in the dark.
  • H5L9, H5L10, H5L11, H5L12, H5L14 and Ustekinumab can competitively block the binding of IL-12 to IL-12R ⁇ 1 on the surface of 293T-IL-12R ⁇ 1&IL-23R cell membranes.
  • the competitive activity of H5L9 is not obvious, and the competitive binding EC 50 of H5L10, H5L11, H5L12, H5L14 and Ustekinumab are 0.3312 ⁇ g/mL, 0.414 ⁇ g/mL, 0.3172 ⁇ g/mL, 0.5320 ⁇ g/mL and 0.3770 ⁇ g/mL, respectively.
  • the binding strength of each antibody competitively blocking IL-12 and IL-12R ⁇ 1 on the cell membrane surface of 293T-IL-12R ⁇ 1&IL-23R are: H5L12, H5L10, Ustekinumab, H5L11, H5L14, H5L9.
  • the results are shown in Table 7 and Figure 20.
  • the results show that Ab123FR1, H8L15 and Ustekinumab can competitively block the binding of IL-12 to IL-12R ⁇ 1 on the cell membrane surface of 293T-IL-12R ⁇ 1 & IL-23R, and the binding of Ab123FR1, H8L15 and Ustekinumab
  • the EC 50 was 1.99 ⁇ g/ml, 1.46 ⁇ g/ml and 1.58 ⁇ g/ml, respectively.
  • the results are shown in Table 8 and Figure 14.
  • the results show that H5L9, H5L10, H5L11, H5L12, H5L14 and Ustekinumab can competitively block IL-23 and 293T-IL-12R ⁇ 1&IL-23R cell membrane surface IL-23 receptor complex
  • the competitive binding EC 50 was 4.252 ⁇ g/mL, 0.6995 ⁇ g/mL, 0.8643 ⁇ g/mL, 0.7748 ⁇ g/mL, 0.8806 ⁇ g/mL and 1.158 ⁇ g/mL, respectively.
  • the binding strength of each antibody competitively blocking IL-23 and IL-23 receptor complex on the surface of 293T-IL-12R ⁇ 1&IL-23R cell membrane is: H5L10, H5L12, H5L11, H5L14, Ustekinumab, H5L9.
  • H5L10, H5L12, H5L11, H5L14 compete to block the binding of IL-23 to the IL-23 receptor complex on the cell membrane surface of 293T-IL-12R ⁇ 1&IL-23R, and their competitive activity is better than Ustekinumab.
  • Example 5 H8L15 effectively inhibits the secretion of IL-17A from spleen cells of mice with spontaneous systemic lupus erythematosus
  • mouse MRL/lpr mouse purchased from Shanghai Slack Laboratory Animal Co., Ltd.
  • hydrated chlorine After aldehyde anesthesia, 75% alcohol immersion and disinfection; transfer to the biological safety cabinet, dissecting the spleen.
  • the spleen was rinsed in a plate containing 1640 complete culture medium to remove fat and fascia tissue.
  • IL-23 can effectively promote the secretion of IL-17A from spleen cells of spontaneous systemic lupus erythematosus model mice. Adding H8L15 while IL-23 treatment can significantly inhibit the secretion of IL-17A, and the inhibitory activity There is a significant dose-dependent relationship, and the pharmacodynamic activity is significantly better than AB123FR1 (sometimes also expressed as Ab123FR1).
  • Example 6 H8L5 effectively improves skin damage in mice with psoriasis
  • C57BL/6 mice purchased from Guangdong Medical Experimental Animal Center
  • mice were randomly divided into normal group, model group, positive control group and H8L15 group after shaved, with 10 mice in each group.
  • the model group was injected subcutaneously with isotype control antibody (ie, human anti-egg lysosome), each dose group of H8L15 was injected with corresponding concentration of H8L15, and the normal group was injected with equal volume of normal saline.
  • C57BL/6 mice were anesthetized by intraperitoneal injection of 3.5% chloral hydrate 7.5ml/kg.
  • mice Normal group mice were injected intracutaneously with normal saline 25 ⁇ l/mouse, and the remaining mice were injected intracutaneously with recombinant human IL- 2310 ⁇ g/25 ⁇ l/mouse, injected once a day for 6 consecutive days.
  • recombinant human IL-23 the cervical vertebrae of each group of mice were dislocated, and a small piece of neck skin (about 0.5 ⁇ 0.5cm) was cut out and placed in formalin tissue fixative for fixation, 24 hours later Make pathological sections of mouse skin, 6 mice in each group.
  • anti-IL-12/IL-23 p40 antibodies such as H8L15 effectively relieve the pathological changes and clinical symptoms of ulcerative colitis model mice.
  • DSS extran sodium sulfate
  • the animal model was established by feeding sterile water through a drinking bottle; in the DSS (from MPBio, item number cat.no: Q1723) group, the animal model was established by feeding 250ml of sterile water through a drinking bottle and adding 2.5g DSS was formulated into 1% DSS solution and established for 9 consecutive days; in the experimental group with antibody, the animal model was prepared by adding 2.5g DSS to 250ml sterile water through a drinking bottle to make a 1% DSS solution, and hIL-23 recombinant protein ( 200ul/100ug/only) intraperitoneal injection (D1-D5, D7-D9) is established daily.
  • DSS from MPBio, item number cat.no: Q1723
  • the experimental index is to investigate the effect of drugs on colitis.
  • the specific index is based on the table of pathological scores of mouse colitis as the standard, see Table 10.
  • Table 10 is the pathological scoring criteria for mouse colitis
  • Table 11 is the establishment method of the mouse model of each experimental group and the antibody dosing schedule
  • the colitis pathological scoring results are shown in Figure 17.
  • H8L15 treatment of DSS combined with recombinant human IL-23 induced colitis mouse skin histopathological observation diagram (HE staining, ⁇ 100) (a: normal group; b: DSS group; c: DSS+hIL-23+hIgG1( 120mg/kg) group; d: DSS+hIL-23+H8L15 (120mg/kg) group; e: DSS+hIL-23+H8L15 (40mg/kg) group as shown in Figure 19.
  • Figure 18 shows the weights of the mice during the experiment.
  • the weights of the mice in the model group continued to decrease, while the weight of the mice in the administration group did not decrease, which was significantly different from the model group.
  • Figure 17 shows the results of the colitis pathology score.
  • the model group showed obvious characteristics of enteritis, while the high and low dose group of the administration group showed statistically significant differences compared with the model group, suggesting that the drug H8L15 is in the treatment of ulcerative It has medicinal effects on colitis.
  • the sequence information is as follows:
  • amino acid sequence of the heavy chain variable region of H5L9, H5L10, H5L11, H5L12, H5L14 is shown in SEQ ID NO:1
  • the nucleotide sequence of the heavy chain variable region of H5L9, H5L10, H5L11, H5L12, H5L14 is shown in SEQ ID NO: 2
  • HCDR1 of H5L9, H5L10, H5L11, H5L12, H5L14 is shown in SEQ ID NO: 3
  • HCDR2 is shown in SEQ ID NO: 4
  • HCDR3 is shown in SEQ ID NO: 5
  • HCDR1 GYSFTTYW (SEQ ID NO: 3)
  • HCDR2 MSPVDSDI (SEQ ID NO: 4)
  • HCDR3 ARRRPGQGYFDF (SEQ ID NO: 5)
  • amino acid sequence of the light chain variable region of H5L9 is shown in SEQ ID NO: 6
  • the nucleotide sequence of the H5L9 light chain variable region is shown in SEQ ID NO: 7
  • LCDR1 of H5L9 is shown in SEQ ID NO: 8
  • LCDR2 is shown in SEQ ID NO: 9
  • LCDR3 is shown in SEQ ID NO: 10
  • LCDR1 QNVGSW (SEQ ID NO: 8)
  • LCDR2 ASS (SEQ ID NO: 9)
  • LCDR3 QQYDIYPFT (SEQ ID NO: 10)
  • amino acid sequence of the light chain variable region of H5L10 is shown in SEQ ID NO: 11
  • the nucleotide sequence of H5L10 light chain variable region is shown in SEQ ID NO: 12
  • amino acid sequence of the light chain variable region of H5L11 is shown in SEQ ID NO: 13
  • the nucleotide sequence of the H5L11 light chain variable region is shown in SEQ ID NO: 14
  • amino acid sequence of the light chain variable region of H5L12 is shown in SEQ ID NO: 15
  • the nucleotide sequence of the variable region of the H5L12 light chain is shown in SEQ ID NO: 16
  • amino acid sequence of the light chain variable region of H5L14 is shown in SEQ ID NO: 17
  • the nucleotide sequence of the H5L14 light chain variable region is shown in SEQ ID NO: 18
  • LCDR1 of L10: QSVGSW is shown in SEQ ID NO: 19
  • LCDR1 of L11, L12, L14: QSVSSW is shown in SEQ ID NO: 20
  • LCDR2 of L10, L11, L12, L14: ASN is shown in SEQ ID NO: 21
  • amino acid sequence of the heavy chain variable region of H8L15 is shown in SEQ ID NO: 24
  • amino acid sequence of the light chain variable region of H8L15 is shown in SEQ ID NO: 25
  • HCDR1 of H8L15 is shown in SEQ ID NO: 26; HCDR2 is shown in SEQ ID NO: 4; HCDR3 is shown in SEQ ID NO: 5; LCDR1 is shown in SEQ ID NO: 27; LCDR2 is shown in SEQ ID NO: 28 Show; LCDR3 is shown in SEQ ID NO: 22; FR-H1 is shown in SEQ ID NO: 29; FR-H2 is shown in SEQ ID NO: 30; FR-H3 is shown in SEQ ID NO: 31; FR- H4 is shown in SEQ I DNO: 32; FR-L1 is shown in SEQ ID NO: 33; FR-L2 is shown in SEQ ID NO: 34, FR-L3 is shown in SEQ ID NO: 35, and FR-L4 is shown in SEQ ID NO: 36
  • HCDR1 GYTFTSYW (SEQ ID NO: 26)
  • HCDR2 MSPVDSDI (SEQ ID NO: 4)
  • HCDR3 ARRRPGQGYFDF (SEQ ID NO: 5)
  • LCDR1 QSVGTW (SEQ ID NO: 27)
  • LCDR2 AAS (SEQ ID NO: 28)
  • LCDR3 QQYNIYPYT (SEQ ID NO: 22)
  • FR-H1 EVQLVQSGAEVKKPGESLKISCQSS (SEQ ID NO: 29)
  • FR-H2 IGWVRQMPGQGLEWIGI (SEQ ID NO: 30)
  • FR-H3 RYNPMFRGQVTMSVDKSSSTAYLQWSSLKASDTAMYYC (SEQ ID NO: 31)
  • FR-H4 WGQGTMVTVSS (SEQ ID NO: 32)
  • FR-L1 EIVLTQSPATLSASPGERATISCRAS (SEQ ID NO: 33)
  • FR-L2 VAWYQQKPGQAPRSLIY (SEQ ID NO: 34)
  • FR-L3 NLQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYC (SEQ ID NO: 35)
  • FR-L4 FGQGTRLEIK (SEQ ID NO: 36)
  • the nucleotide sequence of the heavy chain variable region of H8L15 is shown in SEQ ID NO: 37
  • the nucleotide sequence of the light chain variable region of H8L15 is shown in SEQ ID NO: 38
  • the heavy chain amino acid sequence of H8L15 is shown in SEQ ID NO: 39.
  • the light chain amino acid sequence of H8L15 is shown in SEQ ID NO: 40
  • FR-H1, FR-H2, FR-H3, FR-H4 of H5L9 is the same as that of H8L15; the sequence of FR-L1 is shown in SEQ ID NO: 41; the sequence of FR-L2 is shown in SEQ ID NO: 42 Show; FR-L3 is shown in SEQ ID NO: 43; FR-L4 is shown in SEQ ID NO: 44
  • FR-L1 DIQMTQSPSSLSASVGDRVTITCKAS (SEQ ID NO: 41)
  • FR-L2 LAWYQQKPGKAPKSLIYS (SEQ ID NO: 42
  • FR-L3 RQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO: 43)
  • FR-L4 FGQGTKLEIK (SEQ ID NO: 44)
  • FR-H1, FR-H2, FR-H3, FR-H4 of H5L10 is the same as that of H8L15; the sequence of FR-L1 is shown in SEQ ID NO: 33; the sequence of FR-L2 is shown in SEQ ID NO: 45 Show; FR-L3 is shown in SEQ ID NO: 46; FR-L4 is shown in SEQ ID NO: 36
  • FR-L1 EIVLTQSPATLSASPGERATISCRAS (SEQ ID NO: 33)
  • FR-L2 LAWYQQKPGQAPRSLIYA (SEQ ID NO: 45)
  • FR-L3 LQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYC (SEQ ID NO: 46)
  • FR-L4 FGQGTRLEIK (SEQ ID NO: 36)
  • FR-H1, FR-H2, FR-H3, FR-H4 of H5L11 is the same as that of H8L15; the sequence of FR-L1 is shown in SEQ ID NO: 33; the sequence of FR-L2 is shown in SEQ ID NO: 47 Show; FR-L3 is shown in SEQ ID NO: 46; FR-L4 is shown in SEQ ID NO: 36
  • FR-L1 EIVLTQSPATLSASPGERATISCRAS (SEQ ID NO: 33)
  • FR-L2 LAWYQQKPGQAPRSLIYS (SEQ ID NO: 47)
  • FR-L3 LQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYC (SEQ ID NO: 46)
  • FR-L4 FGQGTRLEIK (SEQ ID NO: 36)
  • FR-H1, FR-H2, FR-H3, FR-H4 of H5L12 is the same as that of H8L15; the sequence of FR-L1 is shown in SEQ ID NO: 33; the sequence of FR-L2 is shown in SEQ ID NO: 45 Show; FR-L3 is shown in SEQ ID NO: 48; FR-L4 is shown in SEQ ID NO: 36
  • FR-L1 EIVLTQSPATLSASPGERATISCRAS (SEQ ID NO: 33)
  • FR-L2 LAWYQQKPGQAPRSLIYA (SEQ ID NO: 45)
  • FR-L3 RQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYC (SEQ ID NO: 48)
  • FR-L4 FGQGTRLEIK (SEQ ID NO: 36)
  • H5L14 (FR-H1, FR-H2, FR-H3, FR-H4 is the same as that of H8L15; the sequence of FR-L1 is shown in SEQ ID NO: 33; the sequence of FR-L2 is shown in SEQ ID NO: 45 As shown; FR-L3 is shown in SEQ ID NO: 46; FR-L4 is shown in SEQ ID NO: 36
  • FR-L1 EIVLTQSPATLSASPGERATISCRAS (SEQ ID NO: 33)
  • FR-L2 LAWYQQKPGQAPRSLIYA (SEQ ID NO: 45)
  • FR-L3 LQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYC (SEQ ID NO: 46)
  • FR-L4 FGQGTRLEIK (SEQ ID NO: 36)
  • amino acid sequence of the light chain of H5L9 is shown in SEQ ID NO: 50
  • amino acid sequence of the light chain of H5L10 is shown in SEQ ID NO: 51.
  • amino acid sequence of the light chain of H5L11 is shown in SEQ ID NO: 52
  • amino acid sequence of the light chain of H5L12 is shown in SEQ ID NO: 53
  • amino acid sequence of the light chain of H5L14 is shown in SEQ ID NO: 54

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PCT/CN2020/105039 2019-07-30 2020-07-28 抗人p40蛋白域抗体及其用途 Ceased WO2021018114A1 (zh)

Priority Applications (12)

Application Number Priority Date Filing Date Title
US17/631,797 US12595300B2 (en) 2019-07-30 2020-07-28 Anti-human P40 protein domain antibody and use thereof
CA3145909A CA3145909A1 (en) 2019-07-30 2020-07-28 Anti-human p40 protein domain antibody and use thereof
PH1/2022/550223A PH12022550223A1 (en) 2019-07-30 2020-07-28 Anti-human p40 protein domain antibody and use thereof
AU2020320910A AU2020320910A1 (en) 2019-07-30 2020-07-28 Anti-human p40 protein domain antibody and use thereof
KR1020227006902A KR20220038775A (ko) 2019-07-30 2020-07-28 항-인간 p40 단백질 도메인 항체 및 이의 용도
BR112022001632A BR112022001632A2 (pt) 2019-07-30 2020-07-28 Anticorpos, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, conjugado de anticorpo, proteína de fusão, kit, usos do anticorpo, composição farmacêutica, métodos in vivo ou in vitro, para preparar o anticorpo e para prevenção, tratamento, tratamento adjuvante e/ou de diagnóstico de doenças autoimunes
JP2022505553A JP7638955B2 (ja) 2019-07-30 2020-07-28 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用
MX2022001305A MX2022001305A (es) 2019-07-30 2020-07-28 Anticuerpo de dominio proteínico p40 anti-humana y uso del mismo.
EP20847243.1A EP4008727A4 (en) 2019-07-30 2020-07-28 HUMANIZED ANTIBODY DIRECTED AGAINST THE P40 PROTEIN DOMAIN AND ITS USE
IL290167A IL290167A (en) 2019-07-30 2022-01-27 Anti-human p40 protein site antibody and use thereof
ZA2022/02380A ZA202202380B (en) 2019-07-30 2022-02-24 Anti-human p40 protein domain antibody and use thereof
JP2025024929A JP2025081517A (ja) 2019-07-30 2025-02-19 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN201910706137.1 2019-07-30
CN201910706137 2019-07-30
CN201911040745 2019-10-29
CN201911040745.X 2019-10-29
CN201911171754.2 2019-11-25
CN201911171754 2019-11-25

Publications (1)

Publication Number Publication Date
WO2021018114A1 true WO2021018114A1 (zh) 2021-02-04

Family

ID=73735954

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/105039 Ceased WO2021018114A1 (zh) 2019-07-30 2020-07-28 抗人p40蛋白域抗体及其用途

Country Status (13)

Country Link
US (1) US12595300B2 (https=)
EP (1) EP4008727A4 (https=)
JP (2) JP7638955B2 (https=)
KR (1) KR20220038775A (https=)
CN (1) CN112079922B (https=)
AU (1) AU2020320910A1 (https=)
BR (1) BR112022001632A2 (https=)
CA (1) CA3145909A1 (https=)
IL (1) IL290167A (https=)
MX (1) MX2022001305A (https=)
PH (1) PH12022550223A1 (https=)
WO (1) WO2021018114A1 (https=)
ZA (1) ZA202202380B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12595300B2 (en) 2019-07-30 2026-04-07 Akeso Biopharma, Inc. Anti-human P40 protein domain antibody and use thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118620077B (zh) * 2024-08-13 2024-11-12 苏州百道医疗科技有限公司 一种抗p40重组兔单克隆抗体及其应用
WO2026062296A1 (en) * 2024-09-23 2026-03-26 Ose Immunotherapeutics Therapy by antagonizing il-7 or cd127, and il-12, il-23, il-12r or il-23r

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
CN101379085A (zh) * 2005-06-30 2009-03-04 艾博特公司 Il-12/p40结合蛋白
CN102177178A (zh) * 2008-08-14 2011-09-07 赛福伦澳大利亚私人有限公司 抗il-12/il-23抗体
CN103275222A (zh) 2013-05-15 2013-09-04 中山康方生物医药有限公司 一种阻断白介素12 p40功能的单克隆抗体及其编码基因和应用
CN109400709A (zh) * 2015-11-13 2019-03-01 广东医科大学 双功能抗体及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
WO2009114040A2 (en) * 2007-09-28 2009-09-17 Centocor Ortho Biotech Inc. Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses
CN103813804A (zh) * 2010-10-06 2014-05-21 Abbvie公司 用于治疗银屑病的方法
TW201242976A (en) 2011-01-07 2012-11-01 Abbott Lab Anti-IL-12/IL-23 antibodies and uses thereof
PT2692865E (pt) * 2012-07-30 2015-02-06 Nbe Therapeutics Llc Identificação mediada por transposição de proteínas funcionais ou de ligação específicas
BR112015013431A2 (pt) * 2012-12-12 2017-11-14 Vasculox Inc anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
GB201720351D0 (en) * 2017-12-06 2018-01-17 Iontas Ltd Selecting for developability in drug discovery
BR112022001632A2 (pt) 2019-07-30 2022-04-19 Akeso Biopharma Inc Anticorpos, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, conjugado de anticorpo, proteína de fusão, kit, usos do anticorpo, composição farmacêutica, métodos in vivo ou in vitro, para preparar o anticorpo e para prevenção, tratamento, tratamento adjuvante e/ou de diagnóstico de doenças autoimunes

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
CN101379085A (zh) * 2005-06-30 2009-03-04 艾博特公司 Il-12/p40结合蛋白
CN102177178A (zh) * 2008-08-14 2011-09-07 赛福伦澳大利亚私人有限公司 抗il-12/il-23抗体
CN103275222A (zh) 2013-05-15 2013-09-04 中山康方生物医药有限公司 一种阻断白介素12 p40功能的单克隆抗体及其编码基因和应用
CN109400709A (zh) * 2015-11-13 2019-03-01 广东医科大学 双功能抗体及其用途

Non-Patent Citations (31)

* Cited by examiner, † Cited by third party
Title
"Epitope Mapping Protocols in Methods in Molecular Biology", vol. 66, 1996
"GenBank", Database accession no. 149233
"GeneBank", Database accession no. 51561
ACIERNO ET AL., J MOL BIOL., vol. 374, no. 1, 2007, pages 130 - 46
ALTSCHUL ET AL., MOL. BIOL., vol. 215, 1990, pages 403 - 410
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 402
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
CHOTHIA ET AL., NATURE, vol. 341, 1989, pages 544 - 546
CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
CLARK, IMMUNOL. TODAY, vol. 21, 2000, pages 397 - 402
DULL TZUFFEREY RKELLY MMANDEL RJNGUYEN MTRONO DNALDINI L.: "A Third Generation Lentivirus Vector with a Conditional Packaging System", J VIROL., vol. 72, no. 11, 1998, pages 8463 - 8471, XP055715204, DOI: 10.1128/JVI.72.11.8463-8471.1998
GONNET ET AL., SCIENCE, vol. 256, 1992, pages 1443 - 45
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1988, pages 5879 - 5883
JELTSCH-DAVID H., AUTOIMMUN REV., vol. 13, no. 9, 2014, pages 963 - 973
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553
LEFRANC ET AL., DEV. COMPARAT. IMMUNOL., vol. 27, 2003, pages 55 - 77
LIU JIANJUN, CHINESE JOURNAL OF CELLULAR AND MOLECULAR IMMUNOLOGY, vol. 4, 1989, pages 29 - 29
MANETTI R ET AL., JOURNAL OF EXPERIMENTAL MEDICINE, vol. 177, no. 4, 1993, pages 1199 - 1204
MARTIN ACRCHEETHAM JCREES AR: "Modelling antibody hypervariableloops: A combined algorithm", PROC NATL ACAD SCI USA, vol. 86, 1989, pages 9268 - 9272
OPPMANN B ET AL., IMMUNITY, vol. 13, no. 5, 2000, pages 715 - 725
PEARSON, METHODS ENZYMOL., vol. 183, 1990, pages 63 - 98
PEARSON, METHODS MOL. BIOL., vol. 132, 2000, pages 185 - 219
PEARSON, METHODS MOL. BIOL., vol. 243, 1994, pages 307 - 31
PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
REICHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
ROSMARIN D ET AL., JOURNAL OF DRUGS IN DERMATOLOGY, vol. 4, no. 3, 2005, pages 318 - 325
See also references of EP4008727A4
SONGSIVILAILACHMANN, CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12595300B2 (en) 2019-07-30 2026-04-07 Akeso Biopharma, Inc. Anti-human P40 protein domain antibody and use thereof

Also Published As

Publication number Publication date
ZA202202380B (en) 2025-06-25
PH12022550223A1 (en) 2022-12-19
MX2022001305A (es) 2022-05-06
JP2022544050A (ja) 2022-10-17
BR112022001632A2 (pt) 2022-04-19
IL290167A (en) 2022-03-01
CN112079922A (zh) 2020-12-15
CN112079922B (zh) 2022-08-12
EP4008727A4 (en) 2024-01-17
JP2025081517A (ja) 2025-05-27
AU2020320910A1 (en) 2022-03-10
CA3145909A1 (en) 2021-02-04
KR20220038775A (ko) 2022-03-29
US20220298235A1 (en) 2022-09-22
EP4008727A1 (en) 2022-06-08
JP7638955B2 (ja) 2025-03-04
US12595300B2 (en) 2026-04-07

Similar Documents

Publication Publication Date Title
JP7759255B2 (ja) ヒトｉｌ４ｒａに対する抗体及びその使用
CN110366560B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途
RU2448979C2 (ru) Антитела человека к дельта-подобному лиганду-4 человека
RU2473564C2 (ru) Антитела человека с высокой аффинностью к фактору роста нервов человека
CN112166121B (zh) 神经生长因子的单克隆抗体及其编码基因和应用
WO2019062832A1 (zh) Tigit抗体、其抗原结合片段及医药用途
CN110267989B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
CN102585002A (zh) 人il-6受体的高亲和力抗体
CN110914304A (zh) Cd96抗体、其抗原结合片段及医药用途
TW201932491A (zh) 抗４－１ｂｂ抗體、其抗原結合片段及其醫藥用途
TWI902681B (zh) 抗ｃｄ７９ｂ抗體、其抗原結合片段及其醫藥用途
JP2025081517A (ja) 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用
CN115461371B (zh) 靶向ox40的抗体及其制备方法和应用
CN112513088A (zh) 抗ox40抗体、其抗原结合片段及其医药用途
WO2022228183A1 (zh) 抗siglec15抗体及其制备方法和用途
WO2021213245A1 (zh) 抗体或其抗原结合片段、其制备方法及医药用途
CN114269788A (zh) 一种能够与人4-1bb结合的分子及其应用
WO2019238074A1 (zh) 一种高亲和力高生物活性的lag-3抗体及其应用
WO2021209066A1 (zh) 特异性抗原结合分子，其制备方法及医药用途
WO2021190582A1 (zh) 一种抗ox40抗体药物组合物及其用途
EA048249B1 (ru) Античеловеческие антитела к домену белка р40 и их применение
CN121005780A (zh) 靶向hla-g的抗体或其抗原结合片段及其应用
CN121591893A (zh) 靶向b7h6的抗体或其抗原结合片段及其应用
CN118525034A (zh) 犬白介素-31受体αI的犬源化抗体
HK40111253A (zh) 抗pacap抗体的组合物和方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20847243

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3145909

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022505553

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 290167

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022001632

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20227006902

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020320910

Country of ref document: AU

Date of ref document: 20200728

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020847243

Country of ref document: EP

Effective date: 20220228

ENP Entry into the national phase

Ref document number: 112022001632

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220128

WWD Wipo information: divisional of initial pct application

Ref document number: 823741

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 17631797

Country of ref document: US